The Life Sciences Report

Diabetes Cell Therapy Merger Nears Close Ahead of Q1 2027 First Patient Dosing

Tue, 20 Oct 2026 00:00:00 PST

Source: Streetwise Reports 10/20/2026

Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) is nearing its proposed merger with Seraxis to form BetaNova, a type 1 diabetes cell therapy company that plans to dose its first patient in Q1 2027. Find out why one analyst sees blockbuster potential in the combined pipeline.

Key Investor Takeaways

Sernova Biotherapeutics Inc. and private Seraxis Holdings Inc. are moving toward closing their merger to form BetaNova Biotherapeutics Inc., with shareholders of each company expected to own about 50%.
The deal pairs Seraxis' stem cell-derived islet cells and cGMP manufacturing with Sernova's Cell Pouch Bio-hybrid Organ, an implantable device designed to house them.
SR-02, the lead program, has FDA clearance of its IND for a Phase 1/2 trial, with first patient dosing targeted for Q1 2027. An IND for the gene-edited SR-03 is targeted for the second half of 2027.
Seraxis named former FDA medical officer Patricia Beaston, MD, PhD, as chief medical officer, a role she will keep at BetaNova after the merger closes.
The companies closed a US$11.2 million financing on October 5, above its US$10 million target, to fund SR-02 manufacturing and trial preparation.
H.C. Wainwright and Research Capital both reiterated positive ratings after the merger was announced, and one analyst sees "blockbuster potential" for SR-02 and SR-03.

Sernova and Seraxis Near BetaNova Merger

Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and private Seraxis Holdings Inc. are moving closer to combining forces on one of type 1 diabetes's hardest problems: replacing the insulin-producing cells the disease destroys, according to an October 19 release. Their merger will create BetaNova Biotherapeutics Inc., a clinical-stage company that pairs one partner's lab-grown islet cells with the other's implantable device to house them.

The update came as Seraxis named Patricia Beaston, MD, PhD, a former U.S. Food and Drug Administration (FDA) medical officer with 24 years at the agency, as its chief medical officer, a role she will keep at BetaNova once the merger closes. The combined company's lead program is set to begin dosing patients in a Phase 1/2 trial in Q1 2027.

From Merger to First Patient

The companies announced the definitive merger agreement on September 8. The deal pairs Seraxis' stem cell-derived pancreatic islets and cGMP manufacturing with Sernova's Cell Pouch Bio-hybrid Organ, an implantable, retrievable device designed to house transplanted islet cells. Shareholders of each company are expected to own about 50% of BetaNova, which will be headquartered in Germantown, Maryland.

The companies said in September that they expected the deal to close in November, subject to shareholder approval. The October 19 release did not update that timing and noted that the merger remains subject to numerous closing conditions. BetaNova is targeting readiness for a Nasdaq listing in Q1 2027.

The lead program, SR-02, has FDA clearance of its Investigational New Drug (IND) application for a Phase 1/2 trial, with first patient dosing targeted for Q1 2027. The initial study will deliver the cells directly into the omentum, a fatty tissue in the abdomen, to assess safety, dosing, and early functional activity. Pairing SR-02 with the Cell Pouch is planned as a later step, subject to regulatory approvals.

Behind it is SR-03, a gene-edited islet cell therapy designed to reduce immune recognition and potentially eliminate the need for chronic immunosuppression. An IND submission for SR-03 is targeted for the second half of 2027.

Raise Tops Its Target

On October 5, the companies closed a US$11.2 million non-brokered financing, above its US$10 million target, with participation from existing shareholders, new investors, and insiders and management of both companies.

Seraxis issued convertible notes and common share purchase warrants, and the notes are expected to convert automatically into BetaNova non-voting common stock when the merger closes. Proceeds will fund cGMP manufacturing of SR-02, preparation for patient enrollment, and clinical development.

Two Analysts Like the Match

H.C. Wainwright & Co. analyst Joseph Pantginis reaffirmed a Buy rating and CA$1 price target on Sernova in a September 14 note following the company's merger webinar. The shares traded at CA$0.10 on September 11, according to the report.

Pantginis called the webinar "supportive of the combined platform, with encouraging SR-02 preclinical data and prior Cell Pouch clinical experience providing a solid foundation for development." He said testing SR-02 alone before pairing it with the Cell Pouch made sense and named SR-02 results, which he expects in the first half of 2027, "the key near-term clinical catalyst."

He noted that earlier Cell Pouch results used islets from deceased donors rather than SR-02, and that reduced immunosuppression is "still something that will need to be demonstrated clinically."

H.C. Wainwright & Co. analyst Joseph Pantginis reaffirmed a Buy rating and CA$1 price target on Sernova.

His target assigns SR-02 and SR-03 each a 10% probability of success, which he said may prove conservative, and he sees "blockbuster potential" for both, with launches anticipated in 2032 and 2033. After closing, the firm expects a reverse split, a financing in the first half of 2027, a U.S. listing, and a switch to U.S. dollar reporting, none of which is in its model. Risks include failed or inconclusive trials, access to capital, and dilution.

Research Capital Corp. analyst Andre Uddin maintained a Speculative Buy rating on September 14, when the shares traded at CA$0.12, and suspended the firm's target "until we see that the merger is approved by shareholders."

"We believe SVA has found the right merger partner," Uddin wrote, citing Seraxis' established cell bank, in-house cGMP manufacturing, cells that don't need a final sorting step, and a donor chosen for transplant compatibility.

He advised investors to watch which immunosuppression protocol the trial uses, since the right balance for patients remains unresolved, and said Sernova shareholders "effectively receive exposure to 50% of a potentially much more valuable biotech platform." His risks include completing the merger, raising substantially more capital, and limited share liquidity.

9.5 Million and Counting

About 9.5 million people worldwide are living with type 1 diabetes, including 1.5 million in the United States, according to Breakthrough T1D, the research and advocacy organization formerly known as JDRF, in figures last updated December 2, 2025. About 199,000 of the U.S. total are under 20, and most Americans with the condition are between 45 and 65.

The group calls type 1 diabetes "one of the fastest-growing, noncommunicable, chronic health conditions on the planet."

The treatment market is growing with it. In a September 2026 report, The Business Research Company valued the global type 1 diabetes market at US$13.5 billion in 2025 and US$15.27 billion in 2026, and forecast US$25.73 billion by 2030, a compound annual growth rate of 13.9%. The report, which covers insulin products and delivery devices, cited closed-loop insulin delivery systems and immunotherapy research among the drivers.

Cell therapies like BetaNova's, which aim to restore the body's own insulin production rather than replace it with injections, are tracked separately. A February 2026 report from The Business Research Company, distributed by Research and Markets, valued the diabetes stem cell therapy market at US$3.01 billion in 2025 and US$3.38 billion in 2026, with a forecast of US$5.29 billion by 2030, or 11.9% annual growth. It cited rising diabetes prevalence, early success in stem cell research, and increasing clinical trial activity, and it lists both Sernova and Seraxis among the companies in the field.[OWNERSHIP_CHART-4790]

Ownership and Share Structure¹

About 10.74% of Sernova before the merger is held by insiders and management, and about 0.04% by institutions. The rest is retail.

Sernova has 377.64 million outstanding shares. Its market cap is approximately CA$43.43 million. Its 52-week range is CA$0.09 to CA$0.20 per share.

Common Questions from Investors

What is the status of the Sernova-Seraxis merger?

The companies announced a definitive merger agreement on September 8 and said then that they expected the deal to close in November, subject to shareholder approval. The merger remains subject to numerous closing conditions, and shareholders of each company are expected to own about 50% of BetaNova.

What catalysts are ahead for BetaNova?

First patient dosing of SR-02 in a Phase 1/2 trial is targeted for Q1 2027, along with readiness for a Nasdaq listing. An IND submission for SR-03 is targeted for the second half of 2027.

How will the SR-02 trial work?

The initial study will deliver the cells directly into the omentum to assess safety, dosing, and early functional activity. Pairing SR-02 with the Cell Pouch is planned as a later step, subject to regulatory approvals.

What financing supports the programs?

On October 5, the companies closed a US$11.2 million non-brokered financing through convertible notes and warrants issued by Seraxis. The notes are expected to convert into BetaNova non-voting common stock at closing, and proceeds will fund SR-02 manufacturing, preparation for patient enrollment, and clinical development.

What are analysts saying?

H.C. Wainwright analyst Joseph Pantginis reaffirmed a Buy rating and CA$1 target on September 14, calling expected SR-02 results "the key near-term clinical catalyst."

Research Capital analyst Andre Uddin maintained a Speculative Buy rating and suspended the firm's target until shareholders approve the merger.

Who is BetaNova's chief medical officer?

Patricia Beaston, MD, PhD, spent 24 years as an FDA medical officer. She is CMO of Seraxis now and will hold the same role at BetaNova once the merger closes.

Important Disclosures:

Sernova Biotherapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Biotherapeutics Inc.
Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: SVA:TSX; SEOVF:OTCQB; PSH0:XETRA, )

Virtual Care Platform Grows US Visits 56%, Eyes Record Quarter

Tue, 20 Oct 2026 00:00:00 PST

Source: Streetwise Reports 10/20/2026

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTCQB; 939:FSE) completed 53,348 patient visits in the third quarter as U.S. visits jumped 56%, and the company expects record quarterly revenue. Find out why one analyst sees the AI telehealth company gaining meaningful traction in the U.S.

Key Investor Takeaways

Rocket Doctor AI completed 53,348 patient visits across the U.S. and Canada in the third quarter, and announced it expects record quarterly revenue.
U.S. visits rose 56% from the second quarter to 6,101, and U.S. clinical hours rose 33% to 2,634.
Canadian visits rose 24% from the same quarter a year earlier to 47,247.
The company has more than 20 in-network agreements covering commercial, Medicare Advantage, and Medicaid plans, giving it potential access to about 24 million covered lives.
Some U.S. revenue is recognized only when cash is collected, so revenue can lag visit growth.
In a September 8 update, Fundamental Research Corp. reiterated a Buy rating on Rocket Doctor AI with a fair value estimate of CA$1.26 per share.
U.S. health spending reached US$5.3 trillion in 2024, according to the Centers for Medicare & Medicaid Services, and 81% of physicians now use AI in their practices, according to the American Medical Association.

53,348 Visits and a Record Quarter in Sight

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTCQB; 939:FSE) announced it completed 53,348 patient visits across the U.S. and Canada in the third quarter, which ended September 30, according to an October 15 release. The company also said it expects to report record quarterly revenue for the period.

Chief Executive Officer Dr. Essam Hamza called the result "a remarkable operational milestone" and said it highlights "the accelerating demand for Rocket Doctor AI's physician-built, AI-powered platform across North America."

US Growth Outruns the Cash Register

U.S. growth led the quarter. Completed U.S. visits rose 56% to 6,101 from 3,911 in Q2, and U.S. clinical hours rose 33% to 2,634 from 1,987.5. In Canada, completed visits rose 24% to 47,247 in Q3 2026 from 37,960 in Q3 2025.

The final U.S. numbers beat the preliminary figures the company gave in its September 14 operational update. That update reported 3,625 U.S. visits and 1,555 clinical hours for July and August alone. The company credited the growth to its multi-payer strategy. It now has more than 20 in-network agreements covering commercial, Medicare Advantage, and Medicaid plans, and it is working to move out-of-network patients and physicians in-network.

Rocket Doctor AI recognizes some U.S. revenue only when cash is collected, so revenue lags behind visit growth.

"While U.S. patient volumes grew significantly in Q2, the associated revenue growth was not immediately reflected in our reported results because of the lag between patient visits, claims processing, and cash collections," Hamza said. "With U.S. patient visits increasing a further 56% in Q3, we expect to begin seeing the financial benefits of that growth as collections catch up with clinical activity. Our expectation of record Q3 revenue is an encouraging indication of that progression."

Built by Doctors, Open to 24 Million Insured Americans

Rocket Doctor AI is a healthcare technology company founded by physicians. Its AI-powered digital health platform and marketplace connect patients with more than 350 physicians, and it has handled more than 800,000 patient visits to date.

The company's U.S. push has gained speed this year. In Q2 results released September 2, Rocket Doctor AI said completed U.S. visits nearly tripled from 1,319 in Q1. Revenue rose 43% from a year earlier to about CA$734,000. The company said its in-network agreements give it access to about 24 million covered lives, including about 10.3 million in California, 10 million in New York, and 3.2 million in Maryland. A June 30 value-based primary care agreement has created the opportunity to add more than 5 million members across nine payers.

Buy Rating Holds as US Traction Builds

In a September 8 update, Fundamental Research Corp. (FRC) Head of Research Sid Rajeev reiterated a Buy rating on Rocket Doctor AI with a fair value estimate of CA$1.26 per share, down from CA$1.55.

He said the company is "gaining meaningful traction in the U.S., with rapidly growing patient volumes, coverage, and provider capacity supporting its virtual care platform." His risk rating was 4 (Speculative).

Rajeev noted that U.S. in-network reach grew to about 24 million covered lives in the second quarter from about 21 million in the first, and that active U.S. clinicians increased to 30 from 19.

Fundamental Research Corp. (FRC) Head of Research Sid Rajeev reiterated a Buy rating on Rocket Doctor AI with a fair value estimate of CA$1.26 per share.

He said the company's falling gross margin reflects the growing share of U.S. business rather than "a structural change in the business model."

U.S. insurers pay Rocket Doctor AI, which then pays physicians, so U.S. margins run at about 15% to 20%. In Canada, provincial plans pay physicians directly, and physicians pay the company a fee, so margins there are about 85% to 90%.

He also said the stock trades at a 56% discount to peers on forward revenue (1.0 times versus 2.3 times) and a 54% discount on forward EBITDA (8.7 times versus 18.9 times). Rajeev cautioned, however, that "the slower-than-expected revenue ramp, rising marketing costs, funding requirements, and potential dilution remain key risks."

A US$5.3 Trillion Problem Meets a Virtual Fix

U.S. health spending rose 7.2% in 2024 to US$5.3 trillion, or US$15,474 per person, according to the Centers for Medicare & Medicaid Services. That is 18% of gross domestic product. CMS projects spending will grow an average of 5.4% a year through 2034, reaching 20.6% of GDP.

The country is also short of doctors. The Association of American Medical Colleges projected in 2024 a shortage of up to 86,000 physicians by 2036, including as many as 40,400 in primary care.

Grand View Research expects the global telehealth market to reach US$87.7 billion this year and US$187.5 billion by 2033, a compound annual growth rate of 11.5%. North America made up 45.2% of the market in 2025. In February, the Consolidated Appropriations Act, 2026, extended Medicare's telehealth flexibilities through December 31, 2027. These flexibilities let patients be seen from home anywhere in the country and keep payment for audio-only visits.

Doctors are adopting AI quickly. In a March American Medical Association survey, 81% of physicians said they use AI in their practices, up from 38% in 2023, the AMA reported. They use it most to summarize medical research (39%), write discharge instructions, care plans, and progress notes (30%), and document billing codes, charts, and visit notes (28%).

"AI has quickly become part of everyday medical practice," AMA Chief Executive Officer Dr. John Whyte said.

Hospitals are moving as well. A January study in The American Journal of Managed Care found that 62.6% of U.S. hospitals on Epic's electronic health records had adopted ambient AI tools, which listen to visits and draft clinical notes. [OWNERSHIP_CHART-10594]

Ownership and Share Information¹

Rocket Doctor AI Inc. has a market cap of approximately CA$54.56 million, with 105.31 million shares outstanding. The company's 52-week range is CA$0.48-CA$0.98.

Management and insiders own 4.07% of shares, institutions own 0.23%, and the rest is retail.

Common Questions from Investors

What drove Rocket Doctor AI's third-quarter growth?

U.S. visits rose 56% from the second quarter, and the company credited its multi-payer strategy and expanding in-network coverage for the gain. Canadian visits rose 24% from the same quarter a year earlier.

Why does revenue lag behind patient visits?

Rocket Doctor AI recognizes some U.S. revenue only when cash is collected. Growth in second-quarter visits didn't show up right away in reported results. The company expects collections to catch up in the third quarter, producing record revenue.

There is an inherent time gap between clinical activity (the patient visit), claim submission, insurance claims adjudication/processing, and final payment collection — a process that can take several weeks to months. While visit volumes increase immediately, reported revenues only reflect these visits once payments clear.

How large is Rocket Doctor AI's U.S. reach?

Its in-network agreements give it access to about 24 million covered lives, including about 10.3 million in California, 10 million in New York, and 3.2 million in Maryland.

What does the analyst covering Rocket Doctor AI think?

Fundamental Research Corp.'s Sid Rajeev rates the stock a Buy with a fair value estimate of CA$1.26 per share and a risk rating of 4 (Speculative). He cited strong U.S. traction but flagged the company's funding needs and potential dilution as key risks.

What is driving demand for telehealth and AI in health care?

U.S. health spending rose 7.2% in 2024 to US187.5 billion by 2033.

What are the next catalysts for Rocket Doctor AI?

The formal third-quarter financial results should confirm whether revenue hit a record. Investors will also watch for more in-network agreements and for progress moving out-of-network patients and physicians in-network.

Important Disclosures:

Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc.
Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: AIDR:CSE; AIRDF:OTCQB; 939:FSE, )

NervGen Kicks Off Pivotal Phase 3 Test of NVG-291 in Chronic Spinal Cord Injury

Fri, 16 Oct 2026 00:00:00 PST

Source: Streetwise Reports 10/16/2026

NervGen Pharma Corp. (NGEN:NASDAQ) has dosed the first patient in its pivotal Phase 3 trial of NVG-291 in chronic spinal cord injury, with topline data expected in the first half of 2028. Find out why one newsletter writer says investors may face a long wait.

Key Investor Takeaways

NervGen dosed the first participant on Oct. 12 in RESTORE, its Phase 3 registrational study of NVG-291 in chronic cervical spinal cord injury.
The roughly 150-patient study uses hand function, measured by GRASSP Quantitative Prehension, as its primary endpoint. Enrollment is expected to finish in the second half of 2027, with topline data in the first half of 2028.
NervGen aligned with the FDA on the trial design, and NVG-291 holds FDA Fast Track and EMA Orphan Drug designations for SCI.
In the Phase 1b/2a CONNECT SCI study, NVG-291 significantly improved a measure of hand muscle nerve signaling versus placebo, while the GRASSP hand function score trended positive without reaching statistical significance.
All three analysts who have rated NervGen in the past three months rate it a Buy, according to TipRanks.
Newsletter writer Chen Lin expects the company to need more funding before 2028.
About 305,000 people in the United States live with SCI, and the global SCI therapeutics market is projected to reach US$10.7 billion by 2031.

NervGen Launches Pivotal Test of Its Spinal Cord Repair Drug

NervGen Pharma Corp. (NGEN:NASDAQ) has dosed the first participant in RESTORE, its Phase 3 registrational study of NVG-291 in people living with chronic cervical motor-incomplete spinal cord injury (SCI), the company announced in an Oct. 12 release.

"Dosing the first participant in RESTORE marks a critical milestone for NervGen," said CEO Adam Rogers, MD.

Inside the RESTORE Study

The multicenter, randomized, double-blind, placebo-controlled study is expected to enroll about 150 participants across the United States and Canada. Eligible participants are one to ten years past a traumatic SCI, with a motor level of C7 or higher and an ASIA Impairment Scale grade of C or D. They will be randomized 1:1 to receive once-daily subcutaneous injections of NVG-291 or placebo for 12 weeks, followed by a four-week observation period, with an optional 12-week open-label extension.

The primary endpoint measures hand function using GRASSP Quantitative Prehension, a priority for people with cervical SCI. Secondary endpoints, including blinded participant interviews, assess functional independence and quality of life. NervGen expects to complete enrollment in the second half of 2027 and report topline data in the first half of 2028.

The Data and the Dollars Behind Phase 3

NervGen reached alignment with the FDA on RESTORE's design following an End-of-Phase 2 meeting. NVG-291 holds FDA Fast Track designation and EMA Orphan Drug designation for SCI.

The design builds on the placebo-controlled Phase 1b/2a CONNECT SCI study. In June 2025, NervGen reported topline data from the study's chronic cohort showing a statistically significant increase in hand muscle motor evoked potentials, a measure of nerve signaling, on NVG-291 versus placebo. Its GRASSP hand function score trended positively but did not reach statistical significance. NVG-291 was generally safe and well-tolerated.

To fund development, NervGen priced a US$60 million public offering in May at US$2.50 per share, with each share accompanied by a warrant exercisable at US$3.68.

Wall Street Says Buy, One Investor Says Wait

Analysts covering NervGen remain positive. TipRanks gives the stock a Strong Buy consensus based on two analysts, with an average price target of US$12.50.

H.C. Wainwright's Ram Selvaraju reiterated a Buy on July 14 while trimming his target to US$15 from US$18, and Leerink Partners' Marc Goodman initiated coverage on July 13 with an Outperform rating and a US$10 target.

TD Cowen's Joseph Thome also reiterated his Buy rating on Aug. 13.

Chen Lin, who writes What Is Chen Buying? What Is Chen Selling?, took a more cautious view in an October 12 note. Noting that NervGen expects RESTORE results in the first half of 2028, Lin wrote, "With this plan, they will need to add more money, possibly through ATM or other means, before the data."

Lin called NervGen "one of my biggest losers this year" and said he was "shocked they raised money at such bad terms." Unless the company pursues accelerated approval, he wrote, NervGen is unlikely to have "any significant catalysts until H1 2028."

Lin also pointed to broader pressure on the sector. "Biotechs are getting killed by high interest rates recently," he wrote. "I am hearing some funds are doing forced liquidation now."

The Unmet Need Behind NVG-291

Spinal cord injuries are among the most disabling conditions in neurology. About 20.6 million people worldwide were living with SCI in 2019, with roughly 900,000 new cases that year, according to the Global Burden of Disease Study. In the United States, about 18,000 new injuries occur each year, the National Spinal Cord Injury Statistical Center estimates.

NervGen's target group is a large share of that population. Incomplete tetraplegia, the category RESTORE is enrolling, is the most common type of SCI in the United States, accounting for 47.4% of cases tracked by the center.

The costs are steep. Lifetime costs for a person injured at age 25 range from about US$2 million for those who keep some motor function to more than US$6 million for high tetraplegia. The global SCI therapeutics market is projected to reach US$10.7 billion by 2031, according to Coherent Market Insights.

Yet there are "no approved pharmacologic treatments for SCI," Randall Kaye, MD, NervGen's chief medical advisor, said in a November 2025 release.[OWNERSHIP_CHART-10026]

Ownership and Share Information¹

NervGen Pharma Corp. has a market cap of US$168.27 million, with 107.52 million shares outstanding. The company's 52-week range is US$1.55-US$6.30.

Institutions own 11.24% of shares, while management and insiders own 15.72%. The rest is retail.

Common Questions from Investors

What is the design of the RESTORE Phase 3 study?

RESTORE is a multicenter, randomized, double-blind, placebo-controlled trial enrolling about 150 adults with chronic cervical motor-incomplete SCI. Participants receive daily injections of NVG-291 or placebo for 12 weeks, and the primary endpoint is hand function measured by GRASSP Quantitative Prehension.

When are topline results expected?

NervGen expects to complete enrollment in the second half of 2027 and report topline data in the first half of 2028.

What did earlier clinical data show?

In the Phase 1b/2a CONNECT SCI study's chronic cohort, NVG-291 produced a statistically significant increase in hand muscle motor evoked potentials versus placebo. The GRASSP hand function score trended positive but did not reach statistical significance, and the drug was generally safe and well-tolerated.

How is NervGen funding the trial?

NervGen priced a US$60 million public offering in May at US$2.50 per share, with warrants exercisable at US$3.68. Newsletter writer Chen Lin expects the company will need to raise more money before the 2028 data.

Important Disclosures:

Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: NGEN:NASDAQ, )

MindBio Therapeutics Advances Voice AI Kiosk for Intoxication Detection Toward Commercial Pilot

Tue, 20 Oct 2026 00:00:00 PST

Source: Streetwise Reports 10/20/2026

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:FSE) completes next-generation Edge AI kiosk manufacture, advancing software validation for first commercial pilot in workplace safety screening.

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:FSE) has completed the manufacture of its next-generation Edge AI intoxication detection kiosk, marking progress on its proprietary Voice AI technology for non-invasive drug and alcohol screening.

Key Investor Takeaways

MindBio completed the manufacture of its next-generation Edge AI kiosk on October 14, 2026, advancing beyond the June prototype.
Software validation and testing continue in preparation for a potential first commercial pilot later in 2026.
The technology aims to provide rapid, non-invasive screening for drug and alcohol intoxication in high-risk industries.
Validation efforts compare AI voice predictions against breath alcohol and oral fluid testing methods.
CEO Justin Hanka highlighted the potential for scalable deployment at lower cost and with minimal physical intervention.

Latest News: Kiosk Manufacturing Milestone

In an October 14, 2026, press release, the company announced the completion of the updated hardware kiosk, which improves on a June 2026 prototype. The system supports MindBio's Voice AI software that analyzes human voice characteristics to predict impairment from drug and alcohol consumption.MindBio is now advancing software integration, system testing, and validation of predictive models against established methods such as breath alcohol and oral fluid testing.

The kiosk targets scalable, rapid screening in safety-critical sectors including mining, aviation, construction, heavy transport, and law enforcement. Traditional testing methods are often labor-intensive and invasive; MindBio positions its technology as a potential lower-cost, less-disruptive alternative for high-volume environments.

"We are making significant progress towards delivering an integrated hardware and software solution that has the potential to fundamentally change how organizations approach drug and alcohol intoxication screening," said CEO Justin Hanka in the press release. "Our focus is on developing technology that can be deployed at scale, enabling businesses to screen more people, more frequently, in a fraction of the time and potentially at a significantly lower cost than conventional testing methods."

Hanka continued, "The completion of our next-generation Edge AI kiosk is an important milestone. We are now focused on validating our prediction models, integration of software, and progressing towards a potential first commercial pilot later this year, where we intend to further evaluate the technology in a real-world operating environment against existing on-site testing methods. Our ambition is to develop a commercially scalable technology that not only addresses a significant global market opportunity but also helps organizations create safer workplaces and ultimately save lives."

MindBio Therapeutics Corp. is commercializing AI prediction technologies for intoxication detection via voice analysis. The platform includes Edge AI kiosks with bespoke hardware and software for enterprise deployment. The company has filed patent applications covering multiple aspects of its voice and AI capabilities.

Addiction in Mining: A Serious Danger

MindBio stated that screening for drug and alcohol intoxication at scale can prevent unnecessary harm through the detection of physiological decline. The company offered statistics that estimate a 10-20x increase in suicide risk while heavily intoxicated. It also claims that 40-50% of suicides involve alcohol, noting that the global alcohol harm cost sits at around US$1.6 trillion.

The risk of addiction and drug or alcohol abuse rises due to many factors, like low parental monitoring, peer pressure, socioeconomic status, type of substance, stress, drug availability, and occupation, according to the American Addiction Centers. They cite the mining industry as "particularly conducive to substance abuse," due to job stress, physical demand, and injuries from prolonged work.

The global biotechnology sector is projected to grow exponentially. "The global biotechnology market size was estimated at US$1.55 trillion in 2023 and is projected to reach US$3.88 trillion by 2030, growing at a CAGR of 13.96% from 2024 to 2030," said Grandview Research. In September 2025, Market and Market Analysis considered the AI detector market as "undergoing rapid expansion, with estimates projecting a substantial market value surge from approximately US$0.58 billion in 2025 to US$2.06 billion in 2030."

MindBio's Tech Could Prevent Injury

On February 3, 2026, The Canadian Mining Journal reported that, "Studies in Chile reveal that alcohol consumption among mining workers exceeds 75%, with over 40% classified as problem drinkers." The article noted the potential efficacy of MindBio's kiosks in accident prevention, saying, "A single preventable incident can cost a mining company hundreds of millions in lost production, union boycotts, and insurance and medical expenses."

Knowlton Thomas, for Techcouver, wrote on January 26, 2026, that ". . . Leveraging more than 50 million data points from drug and alcohol clinical trials and proprietary algorithms across over 100 acoustic parameters, MindBio is now commercializing its technology."

A Multi-Sector Future

Currently, MindBio is creating inroads into the mining, aviation, construction, and law enforcement industries. The company is already partnering with mines in South America and is in talks with other industries.

While enterprise and telehealth capacities are in development right now, future plans include disease prediction and health optimization. [OWNERSHIP_CHART-11539]

Ownership & Share Information¹

MindBio Therapeutics Corp. has a market cap of CA$911.79K, with 7.28 million shares outstanding. The company's 52-week range is CA$0.12-CA$4.00.

Management & Insiders own 3.82% of shares, and the remaining 96.18% of shares are held by Retail.

Frequently Asked Questions

What is the status of MindBio's Voice AI kiosk development?

The company has completed the manufacture of the next-generation hardware and is advancing software integration and validation toward a commercial pilot.

Which industries is MindBio targeting with its intoxication detection technology?

Target sectors include mining, aviation, construction, heavy transport, and law enforcement, where workplace safety and regulatory screening needs are significant.

When might the first commercial pilot occur?

MindBio is targeting completion of testing and a potential initial commercial pilot later in 2026.

How does the Voice AI technology work?

The AI analyzes characteristics of the human voice against millions of data points to predict potential impairment associated with drug and alcohol consumption.

What is Edge AI, and how is it used in intoxication detection?

Edge AI is artificial intelligence that processes data locally on a device rather than relying entirely on remote cloud servers. In intoxication detection, Edge AI can analyze voice characteristics to predict potential drug or alcohol impairment. MindBio Therapeutics Corp. is developing Edge AI kiosks that integrate its proprietary Voice AI software with dedicated hardware for workplace screening.

What is Voice AI, and how can it detect drug or alcohol intoxication?

Voice AI uses artificial intelligence to analyze characteristics of human speech, such as acoustic patterns and vocal changes. MindBio Therapeutics is developing technology that uses voice analysis to predict potential impairment associated with drug and alcohol consumption. The company is validating its predictive models against established testing methods, including breath alcohol and oral fluid tests.

What is non-invasive drug and alcohol screening?

Non-invasive drug and alcohol screening refers to methods designed to assess potential intoxication without requiring invasive sample collection. MindBio's Voice AI kiosk aims to screen individuals through voice analysis, potentially reducing the time and physical intervention required by conventional testing methods. The technology's accuracy and effectiveness must be established through validation and real-world testing.

What is software validation in AI technology development?

Software validation is the process of evaluating whether a system performs as intended and produces sufficiently reliable results for its intended use. For AI screening technology, this can include comparing predictions against established testing methods and assessing performance under different conditions. MindBio is conducting software integration, system testing, and validation of its intoxication prediction models ahead of a potential first commercial pilot.

What is a commercial pilot program for an AI technology company?

A commercial pilot program is an initial real-world deployment used to evaluate a technology's performance and suitability for practical use before broader commercialization. It can help a company identify technical issues, assess operational requirements, and gather evidence about how the product performs in its intended environment. MindBio plans to use a potential commercial pilot to evaluate its Voice AI kiosk against existing on-site drug and alcohol testing methods.

Important Disclosures:

MindBio Therapeutics Corp. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of MindBio Therapeutics Corp.
Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: MBIO:CSE; MBQIF:OTCQB; WF6:FSE, )

The FDA Clarified Its Rules for Medical AI. This Stock Could Be on the Right Side of Them

Wed, 14 Oct 2026 00:00:00 PST

Source: Streetwise Reports 10/14/2026

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTCQB; 939:FSE) continues to evolve its physician-led healthcare platform as revised FDA guidance, new state healthcare AI laws, and rising U.S. patient volumes reshape the regulatory and commercial environment.

Key Investor Takeaways

AI healthcare regulations are changing: The FDA's January 2026 guidance provides greater flexibility for certain physician-facing clinical decision-support tools, while states are restricting autonomous AI medical and mental health services.
Rocket Doctor AI's physician-led model could offer a competitive advantage: Its Global Library of Medicine (GLM) incorporates clinician oversight, more than 25,000 hours of physician input, and over 10,000 expert medical reviews.
U.S. patient visits are accelerating: Completed visits increased 196% from Q1 to Q2 2026. July and August visits alone reached 93% of the entire second-quarter total.
Established insurance relationships create potential barriers to entry: Rocket Doctor AI reports access to approximately 24 million potentially covered lives across California, New York, and Maryland, supported by more than 3.5 years of payer and physician infrastructure development.
The regulatory advantage remains a developing investment thesis: The company's physician-centered approach aligns with emerging healthcare AI requirements such as California’s AB 1979 (Bonta), ensuring that a licensed provider exercises independent professional judgment whenever AI output informs patient care. Long-term success depends on regulatory compliance, reimbursement growth, and sustainable revenue.

As AI Healthcare Laws Tighten, Physician-Led Technology Could Gain an Edge

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTCQB; 939:FSE) continues to evolve its physician-led healthcare platform as new FDA guidance and state legislation reshape the regulatory landscape for artificial intelligence in medicine.

Artificial intelligence is entering American healthcare at a time when regulators are increasingly distinguishing between technology that assists physicians and systems that attempt to replace their clinical judgment. That distinction could become important for Rocket Doctor AI Inc., a healthcare technology company whose platform combines artificial intelligence with licensed physicians, virtual medical practices, and established insurance relationships.

On January 6, 2026, the U.S. Food and Drug Administration revised its clinical decision-support guidance, providing additional regulatory flexibility for certain software that offers recommendations to healthcare professionals. Meanwhile, state lawmakers have introduced restrictions on autonomous AI therapy, insurance decisions, and the use of artificial intelligence in patient care.

According to a July 27 report from the Transparency Coalition, 14 new healthcare AI laws had been adopted across 11 states during the first part of 2026, including five states that prohibited AI chatbot-based therapy services. For Rocket Doctor AI, whose Global Library of Medicine (GLM) is designed to support rather than replace physicians, the changing environment raises a significant question: Could keeping doctors involved in medical decisions become a competitive advantage as AI healthcare regulations expand?

FDA Revises Clinical Decision-Support Rules

The FDA's January 6 revised Clinical Decision Support Software Guidance clarified how certain software functions that provide recommendations to healthcare professionals may qualify for exclusion from medical device regulation or benefit from enforcement discretion.

Under the framework, qualifying clinical decision-support software must satisfy requirements that include allowing healthcare professionals to independently review the basis for recommendations rather than relying primarily on the software when making diagnostic or treatment decisions.

According to a January 8 analysis by Covington & Burling LLP, one important change involved software that produces a single clinical recommendation rather than multiple alternatives. Previously, the FDA's interpretation generally favored software presenting several options for clinicians to evaluate. Under the revised guidance, the agency indicated that it would exercise enforcement discretion for certain tools providing a single recommendation when only one option is clinically appropriate, provided other applicable criteria are satisfied.

The FDA also clarified its approach to some clinical documentation tools and emphasized that recommendations should be supported by accepted medical information presented in a format healthcare professionals can meaningfully evaluate.

However, the guidance did not establish a broad exemption for AI healthcare products. Covington noted that the agency retained much of its previous regulatory framework and did not directly resolve questions surrounding newer generative AI applications or consumer-facing medical chatbots. The distinction between clinician-facing decision support and autonomous medical decision-making nevertheless provides an important backdrop for Rocket Doctor AI's technology.

According to the company's October 2026 investor presentation, the GLM has been developed since 2016 with more than 25,000 hours of input from hundreds of clinicians worldwide and more than 10,000 expert medical reviews.

The company describes the technology as capable of supporting diagnostic assessments involving more than 1,000 diseases and 17,000 symptoms, while suggesting laboratory tests, imaging, treatment options, and billing codes.

Rocket Doctor AI also identifies physician oversight of AI recommendations, clinician-vetted content, and clinical safeguards as components of its technology.

These features are consistent with the broader emphasis on clinician involvement, although the company's physician-led approach does not automatically establish that every GLM function qualifies for exclusion from FDA device regulation.

States Move to Restrict Autonomous Medical AI

While the FDA has clarified its approach to certain decision-support technologies, state governments have been developing additional rules governing how artificial intelligence can be used in healthcare. The Transparency Coalition's review of 2026 legislation identified Colorado, Maine, Rhode Island, Tennessee, and Vermont as five states that enacted restrictions on AI chatbot-based therapy.

The measures differ in scope, but generally address the provision of mental health services by automated systems without appropriate licensed professional involvement.

Other states have focused on insurance decisions. Washington, for example, enacted legislation preventing artificial intelligence from serving as the sole basis for denying, delaying, or modifying healthcare services. Utah established requirements involving AI disclosures and independent medical judgment in insurance authorization decisions.

In a May 26 analysis of state healthcare AI legislation, law firm Holland & Knight described a growing emphasis on human oversight, patient disclosure, and restrictions on autonomous clinical decisions.

Technical analyst Stewart Thomson assigned the stock a Strong Speculative Buy rating, with short-, medium-, and long-term price targets of CA$0.80, CA$1.00, and CA$1.60, respectively.¹

Earlier legislation also contributed to this regulatory environment. California's AB1979 addresses misleading representations that an artificial intelligence system holds a healthcare professional license, while Texas's SB 1188 established requirements governing the use of AI by healthcare practitioners, including review of AI-generated records in accordance with Texas Medical Board standards and disclosing the use of AI to patients.

Although those measures originated in the 2025 legislative session, they form part of the expanding state regulatory framework confronting healthcare technology developers in 2026.

The result is an increasingly complex environment in which companies must account for differences between federal medical device regulation, state professional licensing requirements, patient disclosures, and restrictions on specific AI applications.

For businesses that already incorporate licensed physicians into their clinical workflows, those requirements may align more closely with their existing operating models.

However, clinician involvement alone does not guarantee compliance. Individual products must still satisfy the requirements applicable to their functions and the jurisdictions where they operate.

Rocket Doctor's Global Library of Medicine Keeps Physicians Involved

Rocket Doctor AI's business combines its GLM decision-support technology with a digital healthcare platform that allows physicians to independently establish and manage virtual or hybrid medical practices.

Rather than replacing physicians, the company's technology is intended to help them manage clinical workflows, evaluate medical information, reduce administrative tasks, and provide care to patients who may otherwise face barriers to accessing healthcare.

The company's October 1 announcement concerning the CANTech Letter Conference described its physician-built approach and plans to highlight platform innovations, recent milestones, and growth strategy.

Rocket Doctor Inc. founder and CEO Dr. William Cherniak said, "I am excited to share how Rocket Doctor AI is deploying clinician-led, pragmatic AI platforms to streamline workflows, reduce administrative friction, and ultimately improve patient access and outcomes."

The October investor presentation outlined a connected technology platform that includes the GLM, AI-assisted clinical documentation, electronic medical records, patient triage, virtual appointments, and billing services.

Before appointments, the platform can assist with symptom intake, patient assessments, physician matching, and scheduling. During visits, its tools support diagnostic evaluation, documentation, and referrals. After appointments, the system can assist with follow-up care and chronic condition management.

The presentation also identified clinician review before technology releases, physician oversight of AI recommendations, and curated clinical content as safeguards intended to reduce the risks associated with AI-generated medical information.

The company reported that more than 350 physicians had signed onto its digital health platform and that its technology had supported more than 800,000 completed patient visits.

Those figures provide evidence of the platform's operating history, although its future growth will depend on physician adoption, patient demand, reimbursement arrangements, and the performance of its technology.

Alea Health Acquisition Expands Mental Healthcare Strategy

Rocket Doctor AI's January 2026 acquisition of Alea Health added a mental healthcare component to its broader technology strategy. Alea operates a conversational-AI mental health platform built around therapist-led care, combining digital technology with professional mental health services rather than offering autonomous AI therapy as a substitute for licensed providers.

That distinction has become increasingly relevant as states adopt restrictions on AI chatbots offering therapeutic services. Colorado, Maine, Rhode Island, Tennessee, and Vermont enacted laws restricting AI-based therapy services or the use of AI in mental healthcare. The scope varies by state, with provisions addressing autonomous therapy, representations surrounding professional qualifications, and the role of licensed providers in clinical decisions.

Alea's hybrid, therapist-led structure distinguishes it from standalone AI chatbot therapy platforms. The acquisition does not, however, establish that every feature of the platform automatically satisfies each state's requirements.

For Rocket Doctor AI, the acquisition creates an opportunity to broaden its exposure to mental healthcare while extending its existing strategy of using technology alongside healthcare professionals. It also demonstrates why the distinction between AI-assisted treatment and independently delivered AI therapy may become increasingly important as additional states consider legislation.

NIH Funding Supports AI Medical History Development

Rocket Doctor AI has also received outside research support for the continued development of its clinical technology. On June 16, the company announced that its U.S. subsidiary, Treatment.com Inc., had secured second-year funding through a National Institutes of Health-supported Small Business Innovation Research program.

The project, developed in collaboration with Rush River Research, focuses on an AI-powered family medical history tool intended to improve preventive care and identify health risks through more comprehensive patient information.

The two-year project carries a total award value of approximately US$2 million. The second-year extension provides Treatment.com with more than US$250,000 in additional funding, bringing its total program support to more than US$500,000. The agreement extends through May 31, 2027. The technology uses conversational AI and storytelling to collect family medical histories, incorporating genetic, social, cultural, and environmental factors that can influence health outcomes.

The research initially prioritizes African American communities and aims to improve the identification of chronic disease risks through culturally responsive medical information gathering.

Treatment.com founder and Chief Medical Officer Dr. Kevin Peterson said, "By combining our strengths, we are not just advancing technology, we are creating more equitable, human-centered AI systems that better understand how health is shaped by the relationships, families, and communities where people live."

The project also involves further development of the GLM to support analysis of family health risk factors and personalized clinical decision support.

Although NIH funding does not constitute regulatory approval or validation of every GLM application, the award and the competitive renewal provides external confirmation of the perceived value along with continued external research support for a specific clinical AI development program.

Analysts have also pointed to Rocket Doctor AI's expansion and growth potential. ¹In a March 17 analysis, technical analyst Stewart Thomson highlighted the platform's role in expanding healthcare access and assigned the stock a Strong Speculative Buy rating, with short-, medium-, and long-term price targets of CA$0.80, CA$1.00, and CA$1.60, respectively.

On June 11, Fundamental Research Corp. analyst Sid Rajeev reiterated a Buy rating and CA$1.55 price target, identifying U.S. expansion and increasing patient volumes as potential drivers of future growth.

US Patient Visits Nearly Triple as Revenue Grows

Rocket Doctor AI's regulatory positioning comes as the company reports expanding patient activity and revenue. According to its September 1 second-quarter financial results, revenue reached CA$734,028 during the three months ended June 30, 2026, an increase of 43% compared with the corresponding period in 2025.

U.S. completed patient visits rose from 1,319 in the first quarter to 3,911 in the second quarter, representing an increase of approximately 196%. Momentum continued into the following quarter. In a September 14 operational update, Rocket Doctor AI reported 3,625 completed U.S. patient visits during July and August, equivalent to 93% of the total recorded throughout the entire second quarter.

Clinical hours reached 1,555 during those two months, compared with 1,987.5 hours during the preceding three-month period.

The company's October presentation estimated approximately 5,438 U.S. visits for the full third quarter based on prevailing monthly averages. That figure was identified as an estimate rather than a confirmed quarterly result.

Rocket Doctor AI cautioned that increasing patient visits does not necessarily translate immediately into recognized revenue. The company recognizes certain U.S. revenues when payment is received, creating a timing difference between completed appointments and reimbursement.

Its operating model also permits out-of-network patients to access the platform during the early stages of U.S. expansion. Although reimbursement for these visits is generally not expected, the company may submit claims when possible. Management has indicated that expanding payer relationships and converting more physicians and patients to in-network status could improve reimbursement rates and revenue visibility.

Insurance Infrastructure and AI Investment Could Strengthen Competitive Position

Rocket Doctor AI's October investor presentation identified approximately 24 million potentially accessible in-network covered lives across California, New York, and Maryland, with another 17.8 million targeted through expansion into Florida and Texas. These figures represent potential patient access rather than guaranteed revenue. The company has spent more than 3.5 years developing payer relationships, physician credentialing systems, and revenue operations, which it considers barriers to entry for competitors.

The company also highlighted its first value-based primary care agreement with a California independent physician association, covering an initial panel of approximately 30,000 members. The arrangement provides recurring per-member payments alongside compensation for individual visits and offers indirect access to a broader network of more than 5 million potential patients.

Meanwhile, investment in digital healthcare has strengthened. According to a July 13 report from Fierce Healthcare, citing Rock Health research, U.S. digital health companies raised US$7.4 billion during the first half of 2026, up from US$6.4 billion a year earlier. The report emphasized that domain expertise, integrated workflows, and established partnerships are becoming increasingly important competitive advantages as AI technology becomes more accessible.

For Rocket Doctor AI, the combination of physician-led technology, insurance infrastructure, and clinical oversight could become increasingly valuable as healthcare regulations evolve. The FDA's revised guidance provides flexibility for certain clinical decision-support tools, while state legislation places greater emphasis on licensed professional involvement and accountability. However, the company's model does not automatically qualify its products for regulatory exemptions, and compliance requirements remain dependent on individual applications and jurisdictions. [OWNERSHIP_CHART-10594]

Financial performance also remains a consideration. Despite a 43% year-over-year revenue increase, Rocket Doctor AI reported a CA$6.67 million net loss in Q2 2026, compared with CA$2.69 million a year earlier. Its ability to translate growing patient volumes into sustainable revenue will depend on reimbursement collection, payer expansion, and physician adoption. Whether its established infrastructure and physician-centered approach ultimately create a durable competitive advantage will become clearer as new regulations take effect and U.S. operations mature.

Ownership & Share Information²

Rocket Doctor AI Inc. has a market cap of approximately CA$56.87, with 101.55 million shares outstanding. The company's 52-week range is CA$0.52-CA$0.98.

Management & Insiders own 4.24% of shares.

Frequently Asked Questions About Rocket Doctor AI Stock and Healthcare AI Regulations

What is Rocket Doctor AI, and why could new FDA regulations benefit the company?

Rocket Doctor AI Inc. develops physician-led artificial intelligence technology designed to improve healthcare access and clinical decision-making. The FDA's January 2026 clinical decision-support guidance provides greater regulatory flexibility for certain AI tools that assist licensed healthcare professionals rather than independently making medical decisions. Rocket Doctor AI's physician-centered approach could position it favorably as healthcare AI regulations evolve, although compliance and regulatory exemptions must be evaluated for individual products.

What is the Rocket Doctor AI stock price target?

On June 11, 2026, Fundamental Research Corp. analyst Sid Rajeev reiterated a Buy rating and CA$1.55 price target for Rocket Doctor AI.

¹Technical analyst Stewart Thomson assigned the stock a Strong Speculative Buy rating on March 17, with price targets of CA$0.80 in the short term, CA$1.00 in the medium term, and CA$1.60 in the long term. These are historical analyst opinions, not guarantees of future share performance.

How does Rocket Doctor AI's Global Library of Medicine (GLM) work?

The Global Library of Medicine is an AI-powered clinical decision-support system developed with more than 25,000 hours of input from hundreds of clinicians and over 10,000 expert medical reviews. The technology supports assessments involving more than 1,000 diseases and 17,000 symptoms, while providing suggestions for diagnostic testing, imaging, and treatment. Licensed physicians retain oversight of AI-generated recommendations, distinguishing the company's approach from fully autonomous medical AI systems.

How do new state AI healthcare laws affect Rocket Doctor AI and Alea Health?

New healthcare AI laws in states including California, Texas, Colorado, and Maine emphasize professional licensing, physician oversight, patient safety, and restrictions on autonomous AI therapy. Rocket Doctor AI's physician-led platform and its Alea Health mental healthcare business incorporate licensed healthcare professionals into their service models. Alea's therapist-led approach differs from standalone AI therapy chatbots targeted by several state restrictions, although compliance depends on the specific laws and platform functions.

How many patients and doctors use Rocket Doctor AI?

According to its October 2026 investor presentation, Rocket Doctor AI's platform has supported more than 800,000 completed patient visits and has signed more than 350 physicians. The company also reports approximately 24 million potentially accessible in-network covered lives across California, New York, and Maryland. These covered lives represent potential insurance-network access rather than existing patients or guaranteed appointments.

How fast is Rocket Doctor AI growing in the United States?

Rocket Doctor AI reported 3,911 completed U.S. patient visits in Q2 2026, compared with 1,319 in Q1, an increase of approximately 196%. During July and August, the company completed another 3,625 visits, reaching 93% of the preceding quarter's total in just two months. Management has cautioned that revenue recognition can lag patient activity because of insurance reimbursement and collection timing.

Did Rocket Doctor AI receive a US$2 million NIH grant?

Rocket Doctor AI's subsidiary Treatment.com Inc. is a key participant in a National Institutes of Health-supported Small Business Innovation Research project with a total award value of approximately US$2 million. The project focuses on AI-powered family medical history collection and preventive healthcare. Treatment.com's direct program support exceeds US$500,000, with second-year funding extending through May 2027. Treatment will obtain rights to the software developed during the study. The grant supports research and development, but does not constitute FDA approval of the company's AI products.

What could give Rocket Doctor AI a competitive advantage over other healthcare AI companies?

Rocket Doctor AI combines proprietary clinical decision-support technology with licensed physicians, insurance relationships, and established reimbursement infrastructure. The company reports spending more than 3.5 years developing its U.S. payer and credentialing operations, which could be difficult for newer competitors to replicate. As regulators increasingly emphasize clinical accountability and human oversight, these existing capabilities may become more valuable, although a lasting competitive advantage has not been established.

What are the biggest risks facing Rocket Doctor AI stock?

Key risks include continued operating losses, delays in insurance reimbursement, physician credentialing requirements, regulatory uncertainty, and competition in the healthcare AI market. Rocket Doctor AI must demonstrate that growing patient visits can generate sustainable revenue while maintaining compliance with federal and state healthcare regulations. Its ability to expand insurance coverage, commercialize GLM technology, and manage operating costs will be important measures of future performance.

Important Disclosures:

Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc.
James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, 2026), Rocket Doctor AI Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$2,500.

2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: AIDR:CSE; AIRDF:OTCQB; 939:FSE, )

Nvidia Commits US$1B to American Science Push in Tech, Energy, and Healthcare

Wed, 14 Oct 2026 00:00:00 PST

Source: Streetwise Reports 10/14/2026

Nvidia Corporation (NVDA:NASDAQ) announced commitments valued at US$1 billion over five years to advance U.S. scientific research and development, including quantum computing, healthcare and energy security, building on its partnerships with national laboratories and the Department of Energy.

Nvidia Corp. (NVDA:NASDAQ) announced on October 8, 2026, commitments valued at US$1 billion to advance U.S. science over the next five years, focusing on superintelligence research and development in quantum computing, healthcare, and energy security.

Key Investor Takeaways

Nvidia's October 8 announcement commits US$1 billion over five years to U.S. super intelligence R&D in quantum computing, healthcare, and energy security, extending long-standing DOE collaborations.
The pledge supports the Genesis Mission and invites the science community to collaborate on computer infrastructure to accelerate discovery and U.S. innovation leadership.
At the October 12 OCP Global Summit, Nvidia opened Vera Rubin architecture designs to the open-source community, with Meta Platforms Inc. (META:NASDAQ) adopting Spectrum-6 Ethernet switches and Cisco Systems Inc. (CSCO:NASDAQ) partnering on new pluggable optics for AI factory scaling.
Nvidia's commitment builds on its long-standing collaborations with U.S. national laboratories and the Department of Energy, while its separate Open Compute Project contributions support the development of next-generation AI infrastructure.
Forward-looking catalysts include ongoing Genesis Mission phase 2 awards and expanded AI infrastructure deployments across U.S. government missions.

US$1 Billion Commitment to US Scientific Leadership

The announcement came during the "Science: A New Golden Age" event in Washington, D.C., where Nvidia highlighted its role as a leading industry partner in the Genesis Mission. At the event, Nvidia founder and CEO Jensen Huang, said, "President Trump's Genesis Mission is launching a new golden age of American discovery. With a US$1 billion investment, Nvidia is putting advanced Super Intelligence in the hands of America's scientists to accelerate breakthroughs in medicine, energy, and materials. This is how America turns scientific leadership into industrial leadership, and innovation into jobs and opportunity for generations."

This move builds on more than two decades of collaboration with U.S. national labs and recent partnerships with the U.S. Department of Energy, including work on the department's largest supercomputer for scientific research at Argonne National Laboratory and support for seven new systems across Argonne and Los Alamos National Laboratories.

Just days later, on October 12, 2026, Nvidia contributed key Vera Rubin rack and compute tray designs to the Open Compute Project through its MGX architecture, enabling system builders to develop next-generation AI factory infrastructure with open standards for power, cooling, and networking.Partners, including Meta, Alphabet Inc. Class A (GOOGL:NASDAQ), and Cisco, are aiding in advancing related networking and design initiatives for AI factories.

Nvidia's US$1 billion commitment over five years will support higher-education research institutions, efforts to accelerate American quantum leadership, and cloud service providers serving U.S. government needs. The company said the commitment is intended to advance scientific research and U.S. leadership in fields including quantum computing, healthcare, and energy security. Peers such as Meta and Google are focusing resources on scaling AI factories through open networking standards and rack designs at the same OCP event.

Nvidia also participates in Phase 2 Genesis Mission projects covering quantum computing, fusion, accelerator design and microelectronics.

Public metrics show continued hyperscaler demand supporting Nvidia's position, with recent reports noting robust data-center capital expenditure projections.

The AI Sector's Rapid Growth

Investment in AI infrastructure continues to grow as tech companies and government agencies seek greater computing capacity for scientific research, data processing, and further AI development. The U.S. Department of Energy's Genesis Mission is one example of efforts to apply AI and high-performance computing to scientific challenges, including healthcare, energy, materials science, and quantum computing. The initiative brings together public and private sector participants to support research and accelerate scientific discovery.

Infrastructure development is another priority for technology companies as they attempt to accommodate increasingly demanding AI workloads. On October 12, 2026, Meta outlined new open infrastructure initiatives at the Open Compute Project Global Summit, including networking technologies designed to support larger AI deployments.

Timothy Arcuri of UBS reiterated a "Buy" rating and price target of US$300.

Open standards for computing racks, power delivery, cooling, and networking can help system builders develop and integrate infrastructure across different hardware platforms.

These efforts coincide with rising demand for data center capacity and continued investment in computing infrastructure. PwC's Global Data Centre Outlook examines the long-term investment required to expand data center capacity amid growing AI adoption. The sector's development requires both commercial infrastructure expansion and the application of advanced computing to scientific research, with electricity availability, hardware requirements, and the ability to scale computing systems remaining important considerations.

Recent Analyst Coverage is a 'Buy'

According to Marketbeat, October analyst coverage for Nvidia includes:

On October 2, 2026, Aaron Rakers of Wells Fargo & Co. set a price target of US$210.
On October 2, 2026, Joseph Moore of Morgan Stanley set a price target of US$230.
On October 1, 2026, C.J. Muse of Cantor Fitzgerald reiterated an "Overweight" rating, with a price target of US$350.

Further analyst coverage, reported by Tipranks, includes:

On October 9, 2026, Timothy Arcuri of UBS reiterated a "Buy" rating and price target of US$300.
On October 6, 2026, Atif Malik of Citi reiterated a "Buy" rating and price target of US$315.
On October 6, 2026, Daniel Ives of Yorkville Ives & Co. initiated a "Buy" rating and price target of US$300.
On October 5, 2026, Karl Ackerman of Exane BNP Paribas reiterated a "Buy" rating and raised the price target from US$285 to US$345.
On October 1, 2026, Thomas O'Malley of Barclays reiterated a "Buy" rating and price target of US$275.

Catalysts for the Tech Giant

According to Nvidia's September 2026 presentation, upcoming catalysts for the company include the continued rollout of its Vera Rubin AI computing platform. Nvidia has described Vera Rubin NVL72 as delivering up to 30 times better AI factory token throughput and 45 times lower cost per million tokens than its GB300 NVL72 system. Nvidia reported that its Vera CPU is in full production, with shipments underway to partners. The company also said its Groq 3 LPX system is in full production. The company expects CPU revenue to more than double in fiscal 2028, making product deployment and adoption important milestones to monitor.

Nvidia also highlighted NVLink Fusion adoption and its proposed acquisition of Hugging Face for approximately US$12.93 billion (proposed to close in the first half of 2027) as potential growth drivers. The company estimated that NVLink Fusion's potential revenue could approach US$250 billion by the end of the decade, while its planned Hugging Face acquisition is intended to expand access to AI infrastructure and tools. [OWNERSHIP_CHART-10904]

Ownership & Share Information¹

Nvidia Corp. has a market cap of US$5.47 trillion, with 24.10 billion shares outstanding. The company's 52-week range is US$164.27-US$243.37.

Institutions own 71.34% of shares, while Strategic Investors own 0.04%. Management & Insiders own 3.97%, and the remaining 24.65% of shares are held by Retail.

Frequently Asked Questions

Q: What does Nvidia's US$1 billion commitment specifically fund?

A: It funds support for higher-education research institutions, investments in American quantum leadership and cloud providers bolstering U.S. government needs over five years, plus collaboration on Genesis Mission projects in quantum computing, fusion, and microelectronics.

Q: How does this fit with recent AI factory announcements?

A: The science commitment complements the October 12 OCP news on open Vera Rubin designs and partnerships with Meta, Google, and Cisco to scale AI infrastructure efficiently.

Q: Are there direct comparisons to other AI companies?

A: Peers such as Meta and Google are advancing open networking and rack standards at the same summit, while Nvidia additionally directs resources to national labs and academic R&D under the Genesis Mission.

Q: What is the next expected update?

A: Further details on phase 2 Genesis Mission awards and production deployments of Vera Rubin systems with partners.

Q: What is artificial intelligence (AI)?

A: Artificial intelligence is technology that enables computer systems to perform tasks commonly associated with human intelligence, including learning, problem-solving, language processing, and pattern recognition.

Q: What is a data center, and why is it important for AI?

A: A data center is a facility that houses computing equipment, storage systems, and networking infrastructure. Data centers provide the processing capacity needed to train AI models, run AI applications, and manage large volumes of data.

Q: What is high-performance computing (HPC)?

A: High-performance computing uses powerful computers and interconnected processing systems to perform complex calculations at high speeds. It supports applications such as scientific modeling, climate research, drug discovery, and advanced engineering.

Q: What is quantum computing?

A: Quantum computing is a computing approach that uses quantum-mechanical principles to process information. It may help researchers address certain complex problems that are difficult for conventional computers, although practical applications remain under development.

Q: What is an AI accelerator?

A: An AI accelerator is a specialized processor or computing component designed to speed up artificial intelligence workloads, such as training and running machine-learning models. These processors can improve computational efficiency and help data centers handle increasingly demanding AI applications.

Important Disclosures:

As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Alphabet Inc. Class A and Nvidia.
Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: NVDA:NASDAQ, )

Solving a 10,000-Pound Problem: This Company Aims to Reinvent the Brain Scan

Tue, 13 Oct 2026 00:00:00 PST

Source: Streetwise Reports 10/13/2026

Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) is preparing to open its first dedicated brain PET imaging clinic as new Alzheimer's treatments drive demand for earlier, specialized imaging.

Anyone who has undergone a traditional PET/CT scan or watched a family member go through one probably remembers the machine. The patient lies on a narrow table that moves into a large scanner, often in a cold hospital or imaging center room. The equipment itself can weigh thousands of pounds, cost millions of dollars, and require specialized space and infrastructure.

Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) believes that when doctors only need to image the brain, much of that may be unnecessary.

At its first NovaScan Neuroimaging clinic in Davie, Florida, near Fort Lauderdale, patients will instead sit in a chair while a compact PET-only scanner moves into position around their heads.

"The scanner comes to you," Chief Executive Officer Christopher Moreau told Streetwise Reports.

That difference is at the center of the company's plan to make brain PET imaging more comfortable for patients and easier to bring into communities. Moreau said the first NovaScan clinic was expected to begin taking patients shortly. If the model works, he described a goal of at least 100 clinics across the U.S. within two to two-and-a-half years.

"We're marketing to neurologists, geriatricians, psychiatrists," Moreau said. "These are doctors who are ordering these brain PET scans." His pitch to them was considerably simpler: "Send us one patient and see how we do with them. Just send us one patient."

Why Alzheimer's Imaging Has Taken on New Importance

The timing could be important. For years, confirming Alzheimer's disease could give patients and families an answer without necessarily giving physicians many ways to change what came next. New treatments have begun to alter that equation.

Leqembi and Kisunla, two approved antibody treatments, target amyloid plaques in the brain and can slow cognitive decline in eligible patients. Their prescribing information directs treatment to begin in patients with mild cognitive impairment or mild dementia and requires confirmation of amyloid pathology before treatment.

An amyloid PET scan can help provide that confirmation. Patients receive a radioactive tracer that binds to amyloid deposits, allowing the scanner to capture their distribution in the brain. Cerebrospinal fluid (spinal tap) testing can also establish amyloid pathology, but PET imaging is the preferred route through the diagnostic process rather than a universal requirement for every patient.

For Grey Matters, the important change is that physicians now have more reason to identify amyloid while patients may still qualify for treatment. "We know that Alzheimer's is going to be a huge demand that's going to start to go through the system, and we want to help," Moreau said.

Coverage policy has shifted as well. In October 2023, the Centers for Medicare & Medicaid Services removed its restrictive national coverage determination for amyloid PET imaging, including the previous once-per-lifetime limitation under that policy. Coverage decisions moved to Medicare Administrative Contractors, creating a pathway for broader access based on applicable coverage criteria. Both the brain PET scans and the Alzheimer’s treatments are covered by Medicare, Medicaid, and private insurance.

Moreau said existing PET/CT facilities often prioritize abdominal cancer and cardiac imaging, leaving neurological patients competing for appointments. NovaScan's answer is a facility devoted specifically to brain PET imaging.

¹Analyst Stewart Thomson also pointed to Grey Matters' Alzheimer's imaging strategy in a March 26 report, highlighting its plans for a U.S. network of dedicated neuroimaging clinics using brain-specific PET technology.

Thomson rated the company a "Strong Speculative Buy" and set short-, medium-, and long-term targets of CA$0.08,

A Smaller Scanner Changes the Equation

The Florida clinic will use the CareMiBrain system developed by Spain's Oncovision. The U.S. FDA-cleared device is a dedicated brain PET scanner that accommodates patients in a seated or reclined position.

Traditional PET/CT systems combine metabolic PET imaging with CT to provide anatomical information, an important combination when physicians are locating cancer and other abnormalities throughout the body. Grey Matters' argument is that a dedicated brain scan does not need the CT component or require the same large, multipurpose equipment.

The company's presentation listed the CareMiBrain scanner at approximately 662 pounds and its acquisition cost at approximately US$850,000.

It contrasted that with estimated equipment costs of US$3 million to US$5 million for conventional PET/CT systems, which can weigh thousands of pounds and require significant cooling, electrical, structural, and installation infrastructure.

Those figures are company estimates, but they help explain why management believes the smaller scanner could change the economics of opening imaging centers.

Since CareMiBrain does not incorporate a CT component, Grey Matters stated that this results in 25% less radiation exposure than its PET/CT comparison. Patients still receive a radioactive tracer, so the procedure is not radiation-free, and actual exposure depends on the imaging protocol.

The difference patients notice is more immediate. Rather than lying on a narrow table that moves into a large whole-body scanner, they remain seated while the scanner moves around their head.

For an older patient already dealing with cognitive decline or anxiety about a possible Alzheimer's diagnosis, Moreau believes that experience matters.

"The patient experience is huge," he said.

The compact machine also changes where Grey Matters can put its clinics. Instead of constructing specialized imaging facilities around large equipment, management plans to adapt existing medical offices, which already have reception areas, administrative space, and examination rooms that can be used for patient preparation.

"We are going into space that's already existing," Moreau said. "That's the corporate plan."

His longer-term goal is to make the process efficient enough to open a clinic in approximately 90 days and eventually prepare several locations simultaneously.

Florida Becomes the First Test

The inaugural NovaScan clinic is located at the HCA Florida University Medical Office Building on the campus of HCA Florida University Hospital in Davie. Moreau said Florida's concentration of older residents helped drive the decision to launch there.

The approximately 1,750-foot clinic is designed around two on-site staff members, with image interpretation performed remotely. Moreau described private preparation rooms, comfortable seating, and a quieter setting intended to make the visit easier for patients.

Patients will still need physician referrals. NovaScan is not being positioned as a walk-in brain screening service.

Grey Matters announced an agreement with ProScan Reading Services in August to interpret scans from the Florida clinic. ProScan's subspecialty radiologists will provide readings for amyloid imaging and other specified neurological applications, including standardized Centiloid reporting for Alzheimer's evaluations. Moreau said NovaScan aims to return reports within 24 to 48 hours and provide referring physicians with access to images.

Moreau also identified GE HealthCare as the supplier of the Vizamyl amyloid imaging tracer for the Florida operation. Tracer supply is an important logistical consideration because the radioactive materials used in PET imaging have limited usable lifetimes, meaning future clinics must be located within a practical delivery range.

From One Clinic to a National Network

Moreau said the next step after Davie would be a cluster of three or four Florida clinics. Tampa, Miami, and The Villages were among the potential markets he discussed, although he did not present them as finalized locations.

That first cluster would help Grey Matters determine which responsibilities should remain at individual clinics and which can be centralized before the company attempts a broader rollout. The company intends to pursue corporate expansion rather than a conventional franchise model, with Moreau saying larger financing relationships could eventually support groups of new locations.

The first clinic has already provided lessons. Moreau described a municipal licensing delay after officials initially treated the PET-only facility as a conventional PET/CT installation. Because the newer technology did not fit neatly into the existing category, resolving the issue added time to the opening process. Grey Matters separately announced that it received its Florida radioactive materials license in August.

Moreau acknowledged that opening the doors will not automatically fill the appointment book. Physicians need to learn about NovaScan, become comfortable with the technology and service, and begin referring patients.

"Physicians have to get used to us; they've got to hear about us," he said.

That makes the first patient scan the company's next concrete milestone. It would mark the transition from planning a specialized imaging network to operating its first location and begin answering whether the model can be repeated elsewhere. [OWNERSHIP_CHART-9895]

Grey Matters is not trying to introduce physicians to an entirely new medical test. PET imaging is already established, physicians already order it, and new Alzheimer's treatments have increased the importance of identifying amyloid pathology in eligible patients.

The company's bet is that when physicians only need to see the brain, patients may not need the experience, infrastructure, and massive equipment that come with imaging nearly everything else.

Ownership and Share Structure²

Management and insiders own about 11% of the company, and about 21% is owned by institutions. The rest is with retail.

Grey Matters has 10.31 million outstanding shares, a market cap of approximately CA$4.28 million, and a 52-week range of CA$0.335 to CA$0.90

Key Investor Takeaways

Grey Matters is targeting an emerging Alzheimer's imaging opportunity. New treatments, including Leqembi and Kisunla, require confirmation of amyloid pathology before treatment, potentially increasing demand for brain PET imaging.
The NovaScan model is designed around substantially smaller infrastructure. Grey Matters said its approximately 662-pound CareMiBrain scanner costs about US$850,000, compared with its estimate of US$3 million to US$5 million for conventional PET/CT equipment.
Management sees the smaller footprint as key to scaling. The company plans to use existing medical-office space and ultimately aims to open new clinics in approximately 90 days, with a stated goal of at least 100 locations within two to two-and-a-half years.
The Davie clinic is the proof-of-concept. Management has acknowledged that physician adoption and patient volume remain to be demonstrated, making the first patient scan and subsequent referral activity important milestones.
The model still faces execution risk. Expansion depends on physician referrals, financing, regulatory approvals, tracer availability, suitable locations, and Grey Matters' ability to reproduce the economics of its first clinic.

Frequently Asked Questions

What is a brain PET scan?
A brain PET scan uses a radioactive tracer and specialized imaging equipment to show activity or specific biological targets in the brain. In Alzheimer's evaluations, certain PET tracers can be used to detect amyloid plaque.

How is an amyloid PET scan used to diagnose Alzheimer's disease?
An amyloid PET scan can help determine whether amyloid plaque is present in the brain. Confirmation of amyloid pathology is required before eligible patients begin certain Alzheimer's treatments, including Leqembi and Kisunla.

What is the difference between a brain PET scanner and a PET/CT scanner?
Traditional PET/CT combines PET imaging with CT and can be used throughout the body. The CareMiBrain system used by NovaScan is dedicated specifically to brain PET imaging and does not include a CT component.

Does a brain PET scan expose patients to radiation?
Yes. PET imaging requires a radioactive tracer. Grey Matters stated that its CareMiBrain system results in 25% less radiation exposure than its PET/CT comparison because it does not include the additional CT component. Actual radiation exposure depends on the imaging protocol.

Why could the demand for Alzheimer's brain imaging increase?
New Alzheimer's treatments such as Leqembi and Kisunla require confirmation of amyloid pathology before treatment begins. Grey Matters believes the availability of these therapies, along with changes to Medicare coverage policy for amyloid PET imaging, could increase demand for specialized brain imaging.

Important Disclosures:

Grey Matters Health is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Grey Matters Health.
James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 26, 2026

For the quoted article (published on March 26, 2026), Grey Matters Health has paid Street Smart, an affiliate of Streetwise Reports, US$3,000.
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: GREY:CSE; AGNPF:OTCQB; AGW2:XFRA, )

Sernova and Seraxis Bet on BetaNova to Take Diabetes Cell Therapy Into the Clinic

Tue, 06 Oct 2026 00:00:00 PST

Source: Streetwise Reports 10/06/2026

Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and Seraxis Holdings Inc. are moving toward a merger to form BetaNova Biotherapeutics, with a type 1 diabetes cell therapy trial planned for early 2027. Find out why one analyst says Sernova found the right partner.

Key Investor Takeaways

Sernova and Seraxis Holdings Inc. are moving toward a merger to form BetaNova Biotherapeutics Inc., with each company's shareholders expecting to own approximately 50% on a non-diluted basis.
BetaNova would combine Seraxis' stem cell-derived islet programs and cGMP manufacturing with Sernova's Cell Pouch Bio-hybrid Organ.
The companies plan to enroll patients in Q4 2026 for a Phase 1/2 trial of SR-02, with first dosing in Q1 2027 and initial clinical data anticipated in H1 2027.
Other targets include Nasdaq listing readiness in Q1 2027 and an IND submission for the gene-edited SR-03 program in H2 2027.
The September 8 merger release targeted a November 2026 closing, subject to shareholder, court, and Toronto Stock Exchange approval.
A US$11.2 million convertible note financing, above the US$10 million target, closed in connection with the merger, with insiders of both companies taking part.
H.C. Wainwright & Co. reaffirmed a Buy rating and CA$1 price target on September 14. Research Capital Corp. maintained a Speculative Buy and temporarily suspended its target pending shareholder approval of the merger.
About 9.5 million people worldwide live with type 1 diabetes, including 1.5 million in the United States, according to Breakthrough T1D.

Merger Moves Ahead With 2027 Trial in Sight

Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and Seraxis Holdings Inc. are moving toward completion of their proposed merger to form BetaNova Biotherapeutics Inc., with plans to begin dosing patients with a type 1 diabetes cell therapy in Q1 2027, according to an October 5 release.

The combined company would pair Seraxis' stem cell-derived pancreatic islet programs and current Good Manufacturing Practice (cGMP) manufacturing capabilities with Sernova's Cell Pouch Bio-hybrid Organ. On completion, each company's shareholders are expected to own approximately 50% of BetaNova on a non-diluted basis. The companies said the merger remains subject to required approvals and customary closing conditions.

The release set out the milestones the companies are working toward. They include cGMP manufacturing of SR-02, Seraxis' allogeneic stem cell-derived pancreatic islet cells, and enrollment of patients in Q4 2026 for a Phase 1/2 clinical trial. First patient dosing is planned for Q1 2027 under an investigational new drug application (IND) cleared by the U.S. Food and Drug Administration, with initial clinical data anticipated in H1 2027. The companies are also targeting Nasdaq listing readiness in Q1 2027, subject to listing requirements and approvals, and an IND submission in H2 2027 for SR-03, a next-generation gene-edited islet cell program targeting immune evasion.

Sernova President and Chief Executive Officer Jonathan Rigby said the companies believe "BetaNova is positioned to successfully compete with other companies in the T1D cell therapy space by entering the clinic in the near term."

"Our focus is on execution, while deploying capital efficiently," Rigby said in the release.

"As we work toward completion of the Merger, our teams are aligned around a shared mission, a clear development strategy, and a defined set of milestones for 2026 and 2027," said Will Rust, president and chief executive officer of Seraxis.

Inside the BetaNova Combination

Sernova and Seraxis signed a definitive merger agreement on September 7, 2026. According to the September 8 release announcing the deal, the merger would be carried out through a plan of arrangement, and BetaNova would be a U.S.-domiciled company headquartered in Germantown, Maryland. Rigby is to serve as CEO, Rust as president and chief scientific officer, and James Parsons as chief financial officer.

That release targeted a closing in November 2026, subject to approval by Sernova and Seraxis shareholders, the court, and the Toronto Stock Exchange. Noble Capital Markets Inc. is acting as the exclusive financial adviser to Sernova on the merger.

H.C. Wainwright & Co. analyst Joseph Pantginis reaffirmed a Buy rating and CA$1 price target on Sernova.

Sernova describes itself as a clinical-stage company developing a regenerative medicine approach to type 1 diabetes that combines its Cell Pouch Bio-hybrid Organ with therapeutic cells to create a functional surrogate endocrine organ. In the September release, the company said patient treatment and follow-up in its Phase 1/2 study of the Cell Pouch with human donor islets was complete and that all primary and secondary endpoints were met.

Seraxis develops stem cell-derived pancreatic islets under cGMP manufacturing processes. Its lead product, SR-02, is paired with an immune tolerizing strategy, and its follow-on, SR-03, adds gene edits intended to increase compatibility with the host, according to the October 5 release. The company's stated aim is to show the safety and potency of its islets in patients without immune suppression therapy.

Management of Both Companies Buys In

The companies said the milestones are to be supported by a US$11.2 million non-brokered financing that closed in connection with the merger, above the US$10 million they had targeted. It was made into Seraxis and consists of convertible notes and Seraxis common stock purchase warrants. The notes are expected to convert automatically into BetaNova common stock when the merger is completed. The release did not give the conversion price, interest rate, or warrant terms.

Insiders of both companies took part. The release named Dr. Steven Sangha / Arlo Investments, along with Sernova's Rigby, Parsons, Chief Communications Officer Marylyn Rigby, and Vice President of Investor Relations David Burke. From Seraxis, Rust, and Chief Operating Officer Carole Welsch participated, as did existing shareholders and new investors.

"Closing the financing provides the resources to advance the manufacturing activities required to support SR-02 islet cells and prepare for initiation of the Phase 1/2 clinical trial," Rust said.

Type 1 Diabetes: A Growing Patient Base and Treatment Market

About 9.5 million people worldwide are living with type 1 diabetes, including 1.5 million in the United States, according to Breakthrough T1D, the research and advocacy organization formerly known as JDRF, in figures updated December 2, 2025. Of the U.S. total, about 199,000 are under the age of 20, and most Americans with the condition are between 45 and 65.

The organization describes type 1 diabetes as "one of the fastest-growing, noncommunicable, chronic health conditions on the planet" and said its prevalence is increasing across all populations.

Research Capital Corp. analyst Andre Uddin separately maintained a Speculative Buy rating.

The market for treating the disease is expanding with that population. In a report published in September 2026, The Business Research Company estimated the global type 1 diabetes market at US$13.5 billion in 2025 and US$15.27 billion in 2026, and forecast it would reach US$25.73 billion by 2030, a compound annual growth rate of 13.9%.

The firm cited growing adoption of closed-loop insulin delivery systems and rising investment in immunotherapy research as drivers. Its report covers insulin products and devices such as pumps, pens, and glucose meters.

Cell-based approaches, such as the one BetaNova is pursuing, are tracked separately. A February 2026 report from The Business Research Company, distributed by Research and Markets, put the diabetes stem cell therapy market at US$3.01 billion in 2025 and US$3.38 billion in 2026, with a forecast of US$5.29 billion by 2030, or annual growth of 11.9%. It pointed to rising diabetes prevalence, early-stage success in stem cell research, and increasing clinical trial activity, and it named both Sernova and Seraxis among the companies in the field.

Analysts See a Fit in the BetaNova Combination

H.C. Wainwright & Co. analyst Joseph Pantginis reaffirmed a Buy rating and CA$1 price target on Sernova in a September 14 research note following the company's webinar on the proposed merger. The shares traded at CA$0.10 on September 11, according to the report.

Pantginis said the firm considers the webinar "supportive of the combined platform, with encouraging SR-02 preclinical data and prior Cell Pouch clinical experience providing a solid foundation for development." He noted that the Phase 1/2 trial will initially test SR-02 on its own to assess safety and dose response before pairing the cells with the Cell Pouch, which he considered a sensible progression. He identified the SR-02 results expected in the first half of 2027 as "the key near-term clinical catalyst."

The analyst also pointed to gaps in the evidence available to date. He noted that previous Cell Pouch clinical results involved islets from cadaveric donors rather than SR-02, while the prospect of reducing immunosuppression is "still something that will need to be demonstrated clinically."

Pantginis based his CA$1 target on a clinical net present value model that gives both SR-02 and SR-03 a 10% probability of success, which he suggested may prove conservative. He sees "blockbuster potential" for both programs based on anticipated launches in 2032 and 2033. Following completion of the merger, the firm expects a reverse split, financing during the first half of 2027, alongside a U.S. listing and a transition to U.S. dollar reporting, none of which is reflected in its model. Key risks include unsuccessful or inconclusive clinical trials, insufficient access to capital and dilution from future financings.

Research Capital Corp. analyst Andre Uddin separately maintained a Speculative Buy rating on September 14, when the shares traded at CA$0.12. He temporarily suspended the firm's target price and valuation "until we see that the merger is approved by shareholders."

After reviewing Seraxis' pipeline, Uddin wrote, "we believe SVA has found the right merger partner." He said SR-02 and SR-03 complement the Cell Pouch.

He cited Seraxis' established cell bank and internal cGMP manufacturing capabilities, the fact that its cells do not require a final sorting step, and the selection of the original cell donor for transplant compatibility.

Uddin recommended that investors pay close attention to the immunosuppression protocol selected for the upcoming trial because the optimal balance for patients remains unresolved. He wrote that Sernova shareholders "effectively receive exposure to 50% of a potentially much more valuable biotech platform." His risk factors include completing the merger, raising substantially more capital, and limited liquidity in the shares.[OWNERSHIP_CHART-4790]

Ownership and Share Structure¹

About 10.74% of Sernova before the merger is held by insiders and management, and about 0.04% by institutions. The rest is retail.

Top shareholders include Director Steven Sangha with 10.51%, Chief Financial Officer James Parsons with 0.16%, CEO Rigby with 0.06%, and CATAM Asset Management AG with 0.04%.

Sernova has 377.64 million outstanding shares. Its market cap is approximately CA$39.73 million. Its 52-week range is CA$0.09−CA$0.20 per share.

Common Questions from Investors

What is BetaNova Biotherapeutics? BetaNova is the proposed combined company of Sernova and Seraxis. It would be a U.S.-domiciled company based in Germantown, Maryland, with Jonathan Rigby as CEO, James Parsons as chief financial officer, and Will Rust as president and chief scientific officer.

When is the merger expected to close? The September 8 release targeted closing in November 2026. Completion remains subject to approval by both companies' shareholders, the court, and the Toronto Stock Exchange, along with customary closing conditions.

What are the next clinical milestones? The companies plan to enroll patients in Q4 2026 for a Phase 1/2 trial of SR-02, dose the first patient in Q1 2027, and report initial clinical data in H1 2027. An IND submission for SR-03 is targeted for H2 2027.

Will the first trial combine SR-02 with the Cell Pouch? According to H.C. Wainwright analyst Joseph Pantginis' account of the company's webinar, the Phase 1/2 trial will initially test SR-02 on its own to assess safety and dose response before the cells are paired with the Cell Pouch Bio-hybrid Organ.

Will BetaNova list on Nasdaq? The companies are targeting Nasdaq listing readiness in Q1 2027, subject to listing requirements and approvals.

How is the plan being funded? A US$11.2 million non-brokered financing of convertible notes and warrants closed in connection with the merger. Insiders of both companies participated, and the notes are expected to convert into BetaNova common stock when the merger is completed.

What are analysts saying? H.C. Wainwright reaffirmed a Buy rating and CA$1 target on September 14 and called the SR-02 data expected in the first half of 2027 the key near-term catalyst.

Research Capital maintained a Speculative Buy and said Sernova "has found the right merger partner."

Important Disclosures:

Sernova Biotherapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Biotherapeutics Inc.
Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: SVA:TSX; SEOVF:OTCQB; PSH0:XETRA, )

Nektar's Phase 2b Data Shows Durable Eczema, Alopecia Response

Mon, 05 Oct 2026 00:00:00 PST

Source: Streetwise Reports 10/05/2026

Nektar Therapeutics (NKTR:NASDAQ) reports durable Phase 2b responses for rezpegaldesleukin in eczema and alopecia areata, as the Treg-targeted drug advances toward Phase 3.

Nektar Therapeutics (NKTR:NASDAQ) presented new long-term Phase 2b data on rezpegaldesleukin, its new potential treatment for both alopecia and eczema, at the European Academy of Dermatology and Venereology (EADV) Congress 2026.

According to the company, the drug has demonstrated durability and deepening responses in patients with alopecia areata and atopic dermatitis (eczema), which could position the Treg-targeted biologic to supplant current treatment limitations in these markets.

Key Investor Takeaways

Nektar Therapeutics reported Phase 2b durability data at EADV 2026, showing 63-75% maintenance of responses in alopecia areata off-treatment and deepening EASI responses in atopic dermatitis with flexible dosing.
The atopic dermatitis market faces ongoing issues with long-term remission and access, per a recent Dermatology Times review of the 2025 treatment landscape, creating an opportunity for novel mechanisms like Treg stimulation.
Alopecia areata treatments, including JAK inhibitors, contend with safety warnings that may limit adoption, as detailed in PharmExec's review of the changing alopecia areata treatment landscape, highlighting potential for differentiated profiles.
Rezpegaldesleukin's off-treatment benefits and less frequent dosing align with unmet needs for sustained control noted across multiple dermatology analyses.
Phase 3 advancement in both indications, with a third atopic dermatitis study already initiated, provides near-term catalysts into 2027.
Cash position and pipeline focus support execution without immediate dilution pressure, based on prior updates.

EADV 2026 Data on Rezpegaldesleukin

The October 1, 2026, Nektar release detailing the EADV presentations and new Phase 2b results highlighted new long-term data from the Phase 2b REZOLVE-AA study in severe-to-very-severe alopecia areata, along with maintenance data from the Phase 2b REZOLVE-AD study in moderate-to-severe atopic dermatitis.

For alopecia areata, the study's key question was whether hair regrowth would persist after treatment stopped. Patients who completed 52 weeks of rezpegaldesleukin treatment were followed for an additional six months without treatment. Among the eight patients included in the off-treatment analysis, the company reported:

75% (6 of 8) maintained a SALT (Severity of Alopecia Tool) Score of 20 or less after four months off treatment.
63% (5 of 8) maintained a SALT Score of 20 or less after six months off treatment.
The proportion achieving a SALT Score of 10 or less increased from 7% at Week 52 to 19% after six months off treatment.

The SALT scale measures the percentage of scalp hair loss. A SALT Score of 20 or less generally corresponds to at least 80% scalp hair coverage. A score of 10 or less represents a deeper response, with at least 90% scalp hair coverage.

The company also reported that responses continued to develop during the 52-week treatment period. Between Week 36 and Week 52, 29% of patients in the lower-dose group and 31% in the higher-dose group achieved a new SALT Score of 20 or less, compared with none of the patients receiving placebo. This data is particularly relevant because alopecia areata can be chronic and recurrent.

Nektar's Phase 2b population was also notable because the company reported similar efficacy among patients whose current disease episode had lasted less than four years and those whose episode had lasted four years or longer. These findings remain preliminary, particularly because the six-month off-treatment analysis included only eight patients. However, the persistence of response, combined with continued hair regrowth after treatment cessation, is the primary differentiating feature Nektar highlighted at EADV. Nektar had previewed the EADV presentations in its September 28 announcement, which outlined three oral presentations covering rezpegaldesleukin's clinical and biomarker data in dermatological diseases.

"These data demonstrate that one year of treatment with rezpegaldesleukin can result in lasting and even deepening hair regrowth with these same effects continuing for six months off-treatment in the majority of patients," said David Rosmarin, M.D., Chair of the Department of Dermatology and Associate Professor of Dermatology at Indiana University School of Medicine. "As a novel Treg-targeted mechanism, rezpegaldesleukin is designed to address the underlying immune dysregulation in patients with alopecia areata. To date, we have not seen this degree of both sustained benefit and further hair regrowth after treatment cessation with existing systemic therapies for alopecia areata. These findings suggest that rezpegaldesleukin may offer a fundamentally different approach to managing this chronic disorder and could emerge as a preferred first-line treatment option in the future for patients seeking durable disease control."

Arthur He, Ph.D., of H.C. Wainwright & Co. reiterated his opinion, offering a "Buy" rating and price target of US$185.

For atopic dermatitis, the Phase 2b REZOLVE-AD maintenance analysis evaluated whether patients could sustain or deepen improvements using less frequent dosing. Patients who responded during the initial treatment period were transitioned to either monthly or quarterly maintenance dosing.

Nektar reported sustained improvements across several measures, including EASI-75, EASI-90, vIGA-AD 0/1, and itch scores. EASI measures the extent and severity of eczema, while EASI-75 and EASI-90 represent at least 75% and 90% improvements from baseline, respectively. EASI-100 represents complete clearance according to the EASI measure.

The company reported that the percentage of patients achieving EASI-100 increased substantially during maintenance treatment:

Monthly dosing: EASI-100 increased from 4% at the start of maintenance to 22% at Week 52 among re-randomized patients.
Quarterly dosing: EASI-100 increased from 9% to 18% at Week 52.
Among patients who had already achieved an EASI-75 or vIGA-AD response at maintenance baseline, EASI-100 increased from 6% to 30% with monthly dosing and from 14% to 27% with quarterly dosing.

"Rezpegaldesleukin demonstrated a high maintenance of response and further deepening of response that speaks to the unique therapeutic approach of a regulatory Tcell agonist in patients with atopic dermatitis," said Thomas Bieber, M.D., Ph.D., Professor, Department of Dermatology and Allergy, Ludwig-Maximilians University Hospital, Munich, Germany. "With both monthly and quarterly maintenance dosing, new and sustained responses were observed across the key endpoints of EASI-75, vIGA-AD 0/1, and Itch NRS, with some patients achieving complete skin clearance, or EASI-100. These novel data support the ongoing Phase 3 studies and also highlight the importance of a Treg mechanism to address the heterogeneity of disease in atopic dermatitis patients."

Nektar is also evaluating whether patients who respond to induction therapy can eventually be maintained with monthly or quarterly dosing rather than the twice-monthly regimen used during initial treatment. The EADV results build on earlier Phase 2b results. In March 2026, Nektar reported a statistically significant improvement in mean percentage EASI reduction in the 393-patient REZOLVE-AD study.

How Nektar's Treg Approach Addresses Gaps in the Eczema and Alopecia Markets

Rezpegaldesleukin is designed around a different immunological strategy than many currently marketed treatments. Rather than broadly suppressing immune activity or blocking a single inflammatory pathway, the drug stimulates regulatory T cells, or Tregs, which help maintain immune tolerance and regulate excessive immune responses. Nektar describes rezpegaldesleukin as an investigational, first-in-class Treg stimulator that targets the interleukin-2 receptor complex. The objective is to increase the activity and number of regulatory T cells, potentially restoring balance to an immune system that is attacking a healthy body. That approach could be relevant in both diseases, although the clinical evidence is still developing.

Atopic dermatitis has become a considerably more competitive treatment market in recent years. Targeted biologics and other systemic therapies have expanded the options available to patients with moderate-to-severe disease. A 2025 review by Dermatology Times described the field as increasingly focused on targeted, steroid-sparing treatments, while noting that access, affordability, and long-term remission have not yet been achieved. Patient Care Online's review of the atopic dermatitis treatment landscape also reported in 2025 that multiple targeted therapies are now available after years of limited systemic options. That distinction is important for Nektar's potential positioning. Rezpegaldesleukin would not necessarily need to replace existing therapies based solely on initial efficacy. If larger Phase 3 trials confirm the Phase 2b findings, the company's potential differentiation could instead address the durability of response, continued improvement over time, and the ability to maintain responses with less frequent dosing.

Alopecia areata presents a somewhat different, more competitive market. Several JAK inhibitors have changed the treatment landscape by providing systemic options capable of producing meaningful hair regrowth. PharmExec's review of alopecia areata treatments identified baricitinib, ritlecitinib, and deuruxolitinib as key JAK inhibitors currently available, but it also noted boxed warnings concerning malignancy, major adverse cardiovascular events, and serious infections remain for those drugs. That safety issue is important because alopecia areata affects many younger patients. PharmExec noted that although the boxed-warning risks largely originate from data in older rheumatoid arthritis populations, they can still contribute to hesitation among physicians and patients treating a younger population. A separate April 2026 Dermatology Times analysis emphasized that treatment decisions in alopecia areata increasingly require individualized consideration of disease severity, psychosocial burden, treatment expectations, dosing convenience, monitoring requirements, and insurance access.

Against that backdrop, rezpegaldesleukin's potential differentiation is not simply that it can produce hair regrowth. The more important question is whether it can produce durable disease control with a different safety and dosing profile. The current data is not yet sufficient to establish that advantage conclusively. Phase 3 trials will need to demonstrate that the results from relatively small Phase 2b populations translate into larger and more diverse patient groups, while longer follow-up will be necessary to understand long-term efficacy and the drug's safety profile.

"These results continue to grow the body of evidence that Treg stimulation is emerging as a durable and well-tolerated potential therapeutic option in two distinct immune dermatologic patient populations and support rezpegaldesleukin's advancement into pivotal trials in both atopic dermatitis and alopecia areata," said Jonathan Zalevsky, Ph.D., Chief Research and Development Officer at Nektar Therapeutics. "We've now initiated the third Phase 3 study for rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis who have had prior systemic biologic and/or JAK inhibitor treatment experience, and we are initiating the Phase 3 ZENITH AA study in alopecia areata in early 2027."

What's Going on Now?

Rezpegaldesleukin is advancing through the ZENITH AD Phase 3 program for atopic dermatitis and toward the ZENITH AA Phase 3 program for alopecia areata.

Nektar initiated the first two global registrational Phase 3 trials in atopic dermatitis, ZENITH AD-1 and ZENITH AD-2, in July 2026. The company's announcement on the start of the ZENITH AD program said the trials are designed to evaluate patients who are biologic and systemic JAK inhibitor treatment-naive. The company subsequently initiated the third trial, ZENITH AD-3, for patients who have previously received systemic biologic and/or JAK inhibitor treatment. Each study is planned to enroll 510 patients.

The Phase 3 AD program is designed to test rezpegaldesleukin in both treatment-naive and treatment-experienced populations, which could provide data on whether the drug has potential across different stages of the treatment pathway. Nektar has also said that the Phase 3 program is based in part on the Phase 2b REZOLVE-AD data showing continued improvement with monthly and quarterly maintenance dosing. Initial Phase 3 topline data is expected in mid-2028, with the company targeting a potential biologics license application submission in 2029.

For alopecia areata, Nektar plans to initiate the Phase 3 ZENITH AA study in early 2027, planning to enroll approximately 850 patients with severe-to-very-severe alopecia areata and a SALT Score of 20 or less at Week 52, serving as the primary endpoint. That dosing strategy could also become an important part of the product's potential commercial profile. Initial REZOLVE studies used more frequent dosing, while the longer-term data support further evaluation of monthly and quarterly maintenance schedules in patients who respond to treatment.

From a financial perspective, Nektar reported US$1.02 billion in cash and investments in marketable securities as of June 30, 2026. In its Q2 2026 financial results, the company said this provided a cash runway extending into Q3 2028, beyond the initial Phase 3 data readouts expected in mid-2028.

Finally, Nektar also raised US$373.8 million in gross proceeds through an underwritten public offering in April 2026. The stronger balance sheet gives the company additional funding capacity as it moves rezpegaldesleukin through multiple Phase 3 trials, although future financing needs can still depend on development costs, trial timing, and other corporate expenditures.

Analysts Reporting Varying Valuations

Prior to the latest release, on August 14, 2026, Martin Fan, Ph.D., of Wedbush released a report on Nektar, reiterating a "Neutral" rating and a price target of US$80. Fan wrote, "We do not anticipate M&A until at least 2028, and disagree rezpeg can capture meaningful market share among biologic-naïve patients. Even assuming patients and physicians prefer the AE profile for rezpeg, we have difficulty envisioning circumstances in which payors would support rezpeg over a Dupixent biosimilar."

"We remain skeptical on commercial potential, and until further details emerge on Q12W efficacy in AD, we remain on the sidelines regarding shares," the analyst finished.

Wedbush subsequently cut its price target to US$50 from US$80 on September 23 while maintaining its "Neutral" rating.

However, on October 2, 2026, after the release, Arthur He, Ph.D., of H.C. Wainwright & Co. reiterated his opinion, offering a "Buy" rating and price target of US$185. He claimed that the latest results raised his confidence in the company's drug, saying, "Rezpeg has now demonstrated both durability and deepening of response in REZOLVE-AD and REZOLVE-AA studies."

From an investor standpoint, he argued that, "Nektar's enterprise value is approximately US$565M, down from roughly US$1.0B at the September 30 close, with 2Q26 cash and investments of US$1.02B covering about 64% of the market cap, an enticing price tag for potential suitors, in our view."

Nektar's Next Steps

According to the company's investor presentation, the next major clinical milestone is the Phase 3 ZENITH AA program in alopecia areata, which Nektar expects to initiate in early 2027.

For atopic dermatitis, the ZENITH AD program is already underway.

Key upcoming milestones include:

Early 2027: Planned initiation of the Phase 3 ZENITH AA study in alopecia areata.
2027: Additional clinical development and maintenance data from the atopic dermatitis program.
Mid-2028: Nektar expects initial Phase 3 topline data from the ZENITH AD program.
2029: The company is targeting a potential BLA submission for rezpegaldesleukin, subject to positive Phase 3 results and regulatory discussions.

Nektar also presented separate biomarker data at EADV showing that molecular changes associated with rezpegaldesleukin treatment were detectable as early as Week 2 in patients with atopic dermatitis and were significantly correlated with subsequent clinical response. The September 30 biomarker data announcement provides additional detail on the findings. The results provide additional evidence that the drug is engaging its intended Treg-related mechanism, although biomarker findings do not by themselves establish clinical efficacy. [OWNERSHIP_CHART-4170]

Ownership & Share Information¹

Nektar Therapeutics has a market cap of US$1.49 billion, with 34.14 million shares outstanding. The company's 52-week range is US$33.40-US$109.00.

Institutions own 75.80% of shares, while Strategic Investors own 10%. Management & Insiders own 0.4% of shares, and the remaining 13.80% are held by Retail.

Common Questions from Investors

Q: How does rezpegaldesleukin compare to current eczema and alopecia treatments?

A: Unlike many existing options that struggle with durability and safety concerns, the data show sustained and deepening responses with monthly and quarterly maintenance dosing in atopic dermatitis, while alopecia areata patients maintained responses for up to six months after treatment cessation.

Q: What is the status of Phase 3 trials?

A: The third Phase 3 study in treatment-experienced atopic dermatitis patients has begun; the alopecia areata Phase 3 is slated for early 2027.

Q: Are there analyst notes on these data?

A: Recent sell-side coverage includes H.C. Wainwright's October 2 Buy rating and US$185 price target.

Q: How do market challenges factor into the opportunity?

A: Reports from Dermatology Times, Patient Care Online, PharmExec, and others underscore the need for better durability, safety, and access in both eczema and alopecia areata, areas where Nektar's approach may offer advantages.

Q: What is alopecia areata?

A: Alopecia areata is an autoimmune condition in which the immune system attacks hair follicles, causing hair loss that can range from small patches to extensive or complete scalp and body hair loss.

Q: What is atopic dermatitis (eczema)?

A: Atopic dermatitis is a chronic inflammatory skin condition that commonly causes dry, itchy, irritated, and inflamed skin. Moderate-to-severe disease may require systemic treatments such as biologics or other targeted therapies.

Q: What are regulatory T cells (Tregs)?

A: Regulatory T cells are immune cells that help control excessive immune responses and maintain immune tolerance. Therapies designed to stimulate Tregs are being investigated as a way to restore immune balance in autoimmune and inflammatory diseases.

Q: What is a SALT Score in alopecia areata?

A: The Severity of Alopecia Tool (SALT) Score measures the percentage of scalp hair loss in patients with alopecia areata. Lower scores indicate less hair loss, with a SALT Score of 20 or less generally representing at least 80% scalp hair coverage.

Q: What is an EASI score in atopic dermatitis?

A: The Eczema Area and Severity Index (EASI) is a clinical measure used to assess the extent and severity of atopic dermatitis. EASI-75 and EASI-90 indicate at least 75% and 90% improvement from baseline, respectively, while EASI-100 represents complete clearance according to the EASI measure.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: NKTR:NASDAQ, )

Can AI Find the Right Cancer Drug for the Right Patient? This Collaboration Is Putting It to Work

Tue, 06 Oct 2026 00:00:00 PST

Source: Streetwise Reports 10/06/2026

Rakovina Therapeutics Inc. (RKV:TSX.V; RKVTF:OTCPK; 7JO0:FSE) partners with Celvion on AI-driven precision strategies for its ATR inhibitor.

Key Investor Takeaways

Rakovina Therapeutics launched a new AI-driven cancer drug development collaboration with Celvion Therapeutics, using Celvion's EMphora artificial intelligence platform to analyze real-world clinical outcomes and patient data for Rakovina's ATR inhibitor program.
The AI collaboration will search for drug combinations, predictive biomarkers, and patient populations for ATR-targeted cancer therapies, with the companies expecting the work to generate clinically actionable hypotheses for future combination studies and biomarker-driven patient selection.
Rakovina's kt-5000AI ATR inhibitor program has multiple development milestones as outlined in the May 2026 investor presentation, including lead optimization, lead selection, and ongoing partner discussions. The company's development timeline listed an ATR lead selection for Q4 2026 and GLP toxicology and IND-enabling studies for H1 2027.
Rakovina is advancing three AI-powered DNA damage response cancer drug programs, including the kt-5000AI ATR inhibitor, the kt-3000 dual PARP/HDAC program, and the kt-2000AI PARP inhibitor program.
Additional 2026 and 2027 cancer drug development catalysts span all three programs, including continued in vivo studies for the PARP/HDAC program, advancing PARP lead candidate selection, GLP toxicology and IND-enabling studies, and development of strategic pharmaceutical partnerships.

Rakovina Therapeutics Partners With Celvion on AI-Driven ATR Cancer Drug Development

Rakovina Therapeutics Inc. (RKV:TSX.V; RKVTF:OTCPK; 7JO0:FSE) announced a research collaboration with Boston-based Celvion Therapeutics to use Celvion's proprietary EMphora artificial intelligence platform to identify precision medicine strategies for Rakovina's ATR inhibitor program.

The collaboration will use artificial intelligence to examine large-scale clinical outcomes and real-world patient data to identify therapeutic targets that may enhance the activity of Rakovina's ATR inhibitor. The analysis will evaluate potential drug combinations while searching for previously unrecognized therapeutic opportunities, predictive biomarkers, and patient subgroups most likely to benefit from ATR-targeted therapies.

Rakovina and Celvion aim to use the work to improve development efficiency, reduce clinical risk, and accelerate precision cancer drug development.

The companies expect the analysis to generate clinically actionable hypotheses that could be used to prioritize future combination studies, guide biomarker-driven patient selection strategies, and inform the design of subsequent clinical development programs.

"We have learned how to use multiple specialized AI platforms to accelerate the drug discovery and development process rather than relying on a single platform. Our team selects the right tool for each challenge, from generative design to large-scale screening, to develop molecules that exploit vulnerabilities in how cancer cells repair DNA damage," Rakovina Chief Executive Officer Kim Oishi said. "Working with Celvion extends that approach into clinical strategy, using advanced AI to identify the patient populations and drug combinations where our ATR inhibitor program can have the greatest impact."

Celvion Chief Executive Officer Mi Yang said EMphora was developed to derive therapeutic insights from clinical outcomes and existing patient data.

"By collaborating with Rakovina, we have an opportunity to identify combination therapies and biomarkers that may not be apparent through conventional research methods," Yang said. "Our objective is to generate actionable evidence that helps guide smarter clinical development and ultimately benefits patients."

Rakovina President and Chief Scientific Officer Dr. Mads Daugaard said the collaboration would allow the company to evaluate ATR-based combination strategies while examining additional biomarkers and therapeutic targets.

"Synthetic lethality offers tremendous promise in oncology, but its greatest impact will come from identifying the right combinations for the right patients," Daugaard said. "This collaboration gives us the opportunity to rigorously evaluate ATR-based combination strategies while exploring additional biomarkers and therapeutic targets that could further enhance clinical benefit. These insights will help shape the next generation of our development strategy."

Rakovina and Celvion intend to commit scientific, technical, and other resources to the collaboration. As the work progresses and development opportunities are identified, the companies expect to explore potential co-development and economic arrangements for subsequent stages of development.

Rakovina described the collaboration as part of its broader strategy of combining computational biology, translational science, and precision oncology in cancer drug development. The company is focused on developing cancer treatments targeting the DNA-damage response and has established a pipeline of DNA-damage response inhibitors, with the goal of advancing one or more candidates into human clinical trials in collaboration with pharmaceutical partners.

AI Drug Discovery and Oncology Sector

A September 4 report from Google Australia described cancer drug development as a slow and inefficient process, stating that approximately 95% of oncology drugs entering human clinical trials failed to reach approval. The report examined the use of artificial intelligence, cloud computing, machine learning, and three-dimensional human tissue models to improve drug development. It said machine learning could connect molecular tumor maps with laboratory-tested drug responses and clinical outcomes, with the goal of predicting drug efficacy from a tumor's molecular profile. The report identified clinical trial design as an immediate application, stating that predicting which patient groups were most likely to benefit could support smaller, more targeted trials. It said the approach could help prevent viable drugs from being abandoned because they were "trialed on the wrong patient populations."

Technology had become the "biggest structural shift in oncology drug development over the past 5 years," according to David Spigel, MD, president and chief medical officer of Sarah Cannon Research Institute, in a September 30 interview with The American Journal of Managed Care. Spigel discussed AI's potential role as the number of therapies and clinical trials increased. "It's not hard to imagine with the breadth of drugs in development, the number of clinical trials that are increasing, technology is going to be one of the key drivers of helping us sort through that clutter, that traffic jam of competing drugs, competing trials, and patients to get matched to those therapies," he said.

Spigel said the oncology field remained early in determining how AI could be applied across drug development, clinical trial design, patient recruitment, assessment of results, and endpoint discovery. He also discussed increasingly complex trial designs built around biomarker-defined patient subsets and adaptive protocols. Improved molecular testing has allowed clinicians to track treatment response through measures including minimal residual disease in the blood. "We'll probably even get to a place where we understand areas where maybe you don't think you need a target or expression of a marker to predict benefit from a therapy," Spigel said.

The increasing role of patient selection, molecular subtyping, and AI in oncology development was also discussed during a September 28 OncoDaily and ZS webinar on the state of oncology. Matt Furlow, PhD, said aggregate cancer outcomes could conceal unmet needs within particular subtypes, resistant disease, and later treatment lines. The discussion examined more precise molecular subtyping as a way of identifying opportunities within established disease categories.

The webinar also addressed patient-centered approaches to drug discovery. One biotechnology executive participating in the discussion said, "So our whole premise is that clinical trial failure rates are high in part because the wrong patient population is targeted and, thus, the wrong biology is targeted." The approach described during the webinar involved evaluating drug candidates against biological patterns, including genomic patterns associated with better or worse patient outcomes.

Competition around established biological targets had also increased. According to the analysis presented by Furlow, the average number of assets per individual target had doubled between 2010 and 2024. "But commercially, this signals crowding and diminishing differentiation," he said. The discussion described evaluating both therapeutic targets and treatment modalities as one method of identifying less crowded areas for development.

Patient needs remained another focus of oncology portfolio development. "What is the unmet need and what are you hoping to address with what you're bringing to the table?" one biotechnology executive said during the September 30 discussion. The webinar also examined partnerships and platform validation, including a shift among the leading oncology companies analyzed toward earlier-stage deals and platform licensing. For early-stage technology platforms, the discussion identified the need to validate both individual drug candidates and the technologies used to discover them, while also describing a funding gap between promising preclinical research and the clinical evidence sought by investors.

Drug Development Milestones Extend Through 2027

Rakovina's Q2 2026 investor presentation outlined ongoing and upcoming work across three drug development programs, including its ATR program, dual PARP/HDAC program, and PARP program.

The company's kt-5000AI program is developing an ATR inhibitor designed for central nervous system penetration. The program uses generative AI and targets solid tumors, PTEN-deficient cancers, and CNS metastases. According to the presentation, 138 molecules had been predicted, 43 had been synthesized, and leads had been confirmed as potent and selective. CNS penetration and tolerability had also been confirmed in vivo. The company listed 2026 milestones, including in vivo model data at peer-reviewed meetings, lead-optimization results from an expanded AI collaboration, lead selection, and ongoing partner discussions.

Additional data included in the investor presentation showed that candidate ATR inhibitors had varying levels of CNS penetrance, activity, and metabolic stability that the company said were broadly consistent with AI predictions. Compound D showed equal in vivo efficacy compared with ceralasertib, with decreased weight loss and no signs of hematological toxicity. Further optimization of candidate inhibitors was ongoing.

For its kt-3000 program, Rakovina is developing a dual PARP/HDAC inhibitor for PARP-resistant adult and childhood cancers, including Ewing sarcoma. The presentation said kt-3283 demonstrated superior cytotoxicity compared with FDA-approved olaparib and vorinostat, and the program had been published in Clinical Cancer Research and presented at the AACR Annual Meeting in April 2026.

The program also includes a joint venture with NanoPalm that combines Rakovina's AI drug discovery with NanoPalm's self-targeting patterned lipid nanoparticle delivery system. Rakovina said it retains intellectual property rights and described the funding as non-dilutive. Listed 2026 milestones included securing joint venture funding, an ADC partnership, and nano-lipid formulation data at peer-reviewed meetings.

Development work on pLNP-kt-3283 was also continuing. The presentation said the compound could be encapsulated into a patterned lipid nanoparticle designed by the EnsaliX AI platform. Further development included in vitro and in vivo characterization to confirm activity against PARP and HDAC enzymes, determine ADME properties, and assess efficacy against in vivo tumor models.

Rakovina's third program, kt-2000AI, is a brain-penetrant PARP inhibitor using the deep docking platform and targeting breast, ovarian, and prostate cancers. The company said billions of compounds had been screened through Deep Docking, with 389 compounds assessed against PARP. Leads had been confirmed with PARP selectivity and drug-like properties.

The company's broader development timeline detailed work extending into the first half of 2027. In the third quarter of 2026, Rakovina planned in vivo ADME and efficacy work and advanced lead candidate selection for the ATR program, continued in vivo studies for the PARP/HDAC program, and finalized a Saudi joint venture at the corporate level.

For the fourth quarter of 2026, Rakovina listed the selection of an ATR lead, another round of AI output, and advancing lead candidate selection for the PARP program, institutional funding, and participation in the SNO, AACR-NCI-EORTC, and BIO Middle East conferences. [OWNERSHIP_CHART-11193]

In the first half of 2027, the company's timeline called for GLP toxicology and IND-enabling studies for both the ATR and PARP/HDAC programs, lead selection for the PARP program, and continued development of strategic pharmaceutical partnerships.

Ownership and Share Structure¹

Edison Oncology holds approximately 9.9% of Rakovina Therapeutics. Management and reporting insiders account for about 9.64% ownership, with the remainder held by a combination of institutional, retail, and other investors, as previously disclosed in company materials.

As of September 2, 2026, Rakovina Therapeutics had approximately 44.32 million issued and outstanding shares, and the company's market capitalization was approximately CA$10.2 million. Rakovina's shares had traded within a 52-week range of approximately CA$0.09 to CA$0.47 per share.

Frequently Asked Questions About Rakovina Therapeutics, AI Drug Discovery, and Cancer Drug Development

What is Rakovina Therapeutics' new AI cancer drug development collaboration?
Rakovina Therapeutics announced a research collaboration with Celvion Therapeutics to use Celvion's EMphora artificial intelligence platform to analyze large-scale clinical outcomes and real-world patient data for Rakovina's ATR inhibitor program. The work will examine potential drug combinations, therapeutic targets, predictive biomarkers, and patient populations.

How is Rakovina Therapeutics using artificial intelligence for cancer drug discovery?
Rakovina uses specialized AI platforms across its drug discovery and development work. Its pipeline includes the kt-5000AI ATR inhibitor program, the kt-3000 dual PARP/HDAC program, and the kt-2000AI PARP inhibitor program.

What is Rakovina Therapeutics' ATR inhibitor program?
Rakovina's kt-5000AI program is developing an ATR inhibitor designed for CNS penetration. The program targets solid tumors, PTEN-deficient cancers, and CNS metastases and uses generative AI in its drug discovery and lead-optimization work.

What are predictive biomarkers in AI-powered oncology drug development?
In the Rakovina and Celvion collaboration, the EMphora platform will analyze clinical outcomes and real-world patient data to search for predictive biomarkers and patient subgroups most likely to benefit from ATR-targeted therapies.

What are Rakovina Therapeutics' upcoming drug development catalysts?
The company's development timeline listed ATR lead selection and further PARP AI work for Q4 2026. For H1 2027, Rakovina listed GLP toxicology and IND-enabling studies for its ATR and PARP/HDAC programs, PARP program lead selection, and continued development of strategic pharmaceutical partnerships.

What is the role of AI in oncology clinical trials and precision medicine?
Sector sources described AI as being explored across drug development, clinical trial design, patient recruitment, results assessment, and patient selection. The sources also discussed using molecular and clinical data to identify patient groups that could benefit from more targeted cancer trials and therapies.

Why are patient selection and biomarkers important in cancer drug development?
The sector sources discussed increasingly precise molecular subtyping and biomarker-defined patient groups as oncology development became more personalized. Rakovina and Celvion said their collaboration would seek clinically actionable hypotheses to guide combination studies, biomarker-driven patient selection, and subsequent clinical development programs.

What are Rakovina Therapeutics' stock symbols?
Rakovina Therapeutics trades under RKV on the TSX Venture Exchange, 7JO0 on the Frankfurt Stock Exchange, and RKVTF on the OTC Markets.

Important Disclosures:

Rakovina Therapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rakovina Therapeutics Inc.
James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: RKV:TSX.V;RKVTF:OTCPK;7JO0:FSE, )

Aldeyra Plans FDRR to Appeal FDA Reproxalap CRL for Dry Eye

Fri, 02 Oct 2026 00:00:00 PST

Source: Streetwise Reports 10/02/2026

Aldeyra Therapeutics Inc. (ALDX:NASDAQ) announces intent to submit Formal Dispute Resolution Request appealing March 2026 CRL for reproxalap in dry eye disease. Here is a plain-English guide to the FDA appeal process for investors.

Aldeyra Therapeutics Inc. (ALDX:NASDAQ) announced on September 29, 2026, its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs (OND) to appeal the agency's March 16, 2026, Complete Response Letter (CRL) denying approval of reproxalap for dry eye disease.

Key Investor Takeaways

Aldeyra Therapeutics Inc. intends to submit an FDRR in Q4 2026 to appeal the March 2026 CRL for reproxalap in dry eye disease, based on data from nine clinical trials.
The FDRR process allows formal appeal of FDA scientific decisions to higher management levels, with PDUFA target timelines of 30 days for response and possible meetings or panels.
Investors should monitor the Q4 2026 OND meeting and subsequent decision for clarity on next steps, which could include resubmission or additional requirements.
Cash position of US$45.1 million as of June 30, 2026, supports operations into 2029, providing runway through the appeal process.
The appeal focuses on the totality of evidence rather than new trials, distinguishing it from prior CRL recommendations.

Latest News: Aldeyra's Appeal Plan

The company plans to submit the FDRR and hold a meeting with the OND in Q4 2026. Aldeyra has received three CRLs across one initial New Drug Application (NDA) and two resubmissions. The latest CRL cited insufficient evidence of effectiveness from the totality of nine adequate and well-controlled trials, five of which met all multiplicity-controlled primary endpoints. The firm updated its cash runway guidance to extend into 2029 based on US$45.1 million in cash and equivalents as of June 30, 2026.

"We remain steadfast in our commitment to working with the FDA to provide a novel therapeutic approach for the treatment of dry eye disease, a condition often regarded by patients and physicians as inadequately addressed by available therapies," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra Therapeutics. "Based on the activity of reproxalap across a number of clinical trial designs, and against a backdrop of FDA dry eye disease product approvals that have applied considerable discretion, we are optimistic in the outcome of the FDRR."

How the FDA Formal Dispute Resolution Request Process Works

The FDRR is an established FDA pathway under 21 CFR 10.75 and related regulations that lets a sponsor formally appeal a scientific or medical decision, such as a Complete Response Letter, when it cannot be resolved at the division level. In plain English, it is like asking a higher-level manager to review a lower-level decision. The sponsor submits a detailed request explaining why the original ruling should be overturned, supported by existing data or arguments.

For Prescription Drug User Fee Act products like reproxalap, the FDA aims to respond within 30 days of receipt, though actual timelines can stretch if the deciding official seeks extra information, consults experts, or convenes an advisory panel. A meeting with the OND is typically part of the process. If the appeal succeeds, the NDA can be resubmitted with any required additional information; if not, the company may need further trials or other steps.

Aldeyra's decision followed recent Type A and Type D meetings with the Division of Ophthalmology and Office of Specialty Medicine.

The Drug Development Market Needs R&D Funding

The rare-disease market has become an increasingly active area of drug development. The U.S. Food and Drug Administration (FDA) estimates that approximately 25 million to 30 million Americans live with a rare disease, encompassing roughly 10,000 rare diseases and conditions. The agency reported that exactly half of its 46 novel drug approvals in 2025 were for rare diseases, while 123 orphan new molecular entities were approved over the five years through 2025. The FDA also noted that small patient populations, heterogeneous disease characteristics, and limited understanding of natural disease progression can complicate rare-disease clinical trials.

Regulatory approaches are also evolving to address the challenges of rare-disease development. In 2025, the FDA introduced its Rare Disease Evidence Principles, outlining a framework for therapies targeting rare diseases with very small patient populations and significant unmet medical need driven by known genetic defects. The framework allows FDA and developers to consider evidence such as biomarkers, mechanistic data, pharmacodynamic measurements, natural-history studies, and nonclinical models alongside clinical trial results. For rare inherited cardiac disorders, these approaches can be relevant because the number of eligible patients may limit the feasibility of large, conventional randomized trials.

Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

After Aldeyra's announcement, Yale Jen, Ph.D., of Laidlaw & Co. reiterated a "Buy" rating and US$13 target price.

At the same time, J. Edward Moreno of Sherwood News reported contradictory news on January 14, 2026, writing that, "In 2025, announced global biotech deals totaled US$228.4 billion, up from US$132.3 billion in 2024, data from Dealogic shows . . . Just two weeks into 2026, US$9.2 billion in deals have been announced."

According to Moreno, movement is expected in the sector: "As some of the most lucrative drugs lose exclusivity in the next few years, pharmaceutical giants are increasingly shopping around for biotechs to add to their portfolios — and they are more than happy to pay a hefty premium for the right company . . . For some Big Pharma companies, business development spending is now about equal to, or more than, research and development."

The shift toward business-development spending comes as some major pharmaceutical companies have reduced or reprioritized R&D spending. On March 25, 2026, BioSpace's Annalee Armstrong reported that, "R&D spending at the top 16 pharmaceutical companies declined by 3.6% overall in 2025, as many aggressively cut spending and refocused pipelines."

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Analyst Coverage Looks to Appeal

After Aldeyra's announcement, Yale Jen, Ph.D., of Laidlaw & Co. reiterated a "Buy" rating and US$13 target price, writing that, "In our view, the FDRR is a logical next step since the reviewers in the agency may have strong pre-existing opinions on the study setup despite reproxalap was clearly demonstrated to be active in treating DED."

The analyst continued, arguing, "It is definitely worth a different set of eyes to reexamine the totality of clinical data to derive their own conclusions. We believe it will be straightforward if the appeal is granted. If so, a final label would be negotiated, and an NDA resubmission could take place afterward."

Marketbeat has also reported other recent analyst coverage, including:

On September 30, 2026, Matthew Caufield of H.C. Wainwright & Co. reiterated a "Neutral" rating with a price target of US$2.00.
On September 29, 2026, Thomas Shrader of BTIG Research reiterated a "Buy" rating.

What the Appeal Means for Aldeyra and Investors

The company believes that a successful appeal could reopen the path to approval without new trials, potentially accelerating the commercialization of reproxalap. The process carries uncertainty around timing and outcome, but it demonstrates Aldeyra's commitment to leveraging its clinical data package. Aldeyra also continues advancing other pipeline candidates, including ADX-2191 for primary vitreoretinal lymphoma.

Aldeyra remains focused on advancing its RASP modulator platform while navigating the regulatory appeal for reproxalap. [OWNERSHIP_CHART-7011]

Ownership & Share Information¹

Aldeyra Therapeutics Inc. has a market cap of US$74.70 million, with 60.33 million shares outstanding. The company's 52-week range is US$1.07-US$5.93.

Institutions own 61.20% of shares, while Management & Insiders own 3.60% of shares. The remaining 35.20% of shares are Retail.

Frequently Asked Questions

Q: What is the FDRR, and how long does it take?

A: The Formal Dispute Resolution Request is the FDA's formal appeal mechanism for scientific disputes. Sponsors submit arguments to higher FDA officials; for user-fee products, the agency targets a response within 30 days, though meetings and decisions can extend into subsequent quarters depending on complexity.

Q: Why is Aldeyra pursuing this now?

A: Following Type A and Type D meetings, the company believes the existing nine-trial dataset supports approval and warrants higher-level review of the latest CRL.

Q: What happens if the appeal succeeds or fails?

A: Success could allow NDA resubmission without new studies. Failure may require additional data or trials, extending timelines and costs.

Q: How does this affect the company's cash runway?

A: Aldeyra extended guidance to 2029, covering the appeal period and ongoing pipeline work.

Q: What is a Complete Response Letter (CRL) from the FDA?
A: A Complete Response Letter is issued by the U.S. Food and Drug Administration when it determines that an application does not meet the requirements for approval in its current form. A CRL outlines the deficiencies that must be addressed before approval can be reconsidered.

Q: What is a New Drug Application (NDA)?
A: An NDA is the application a drug developer submits to the FDA seeking approval to market a new drug in the United States. It contains information on the drug's safety, effectiveness, manufacturing, labeling, and clinical development program.

Q: What is a PDUFA target action date?
A: A PDUFA target action date is the FDA's goal for completing its review of certain drug applications under the Prescription Drug User Fee Act. These timelines help establish when the agency expects to communicate an action on an application or regulatory matter.

Q: What is a Type A meeting with the FDA?
A: A Type A meeting is an FDA meeting intended to resolve important issues that may otherwise delay a drug development program. These meetings can address disputes, clinical holds, or other critical regulatory questions and provide drug developers an opportunity to discuss the agency's concerns directly.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: ALDX:NASDAQ, )

Satellos Targets Untapped FSHD Market With FDA-Cleared IND for Phase 2 Trial

Tue, 29 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/29/2026

Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) received FDA clearance of its IND application for a planned Phase 2 study of forazapadin in FSHD; US$5M non-dilutive funding and quotes highlight regeneration potential where no therapies exist.

Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) secured FDA clearance on September 24, 2026, of its IND application for forazapadin in facioscapulohumeral muscular dystrophy (FSHD), with a Phase 2 study planned for Q4 2026, positioning the oral AAK1 inhibitor to address a market with no approved disease-modifying therapies while building on positive Duchenne muscular dystrophy (DMD) data.

Key Takeaways

Satellos received FDA IND clearance for a Phase 2 study of forazapadin in FSHD, a disease with no approved disease-modifying therapies, expanding its muscle regeneration platform.
Up to US$5 million in non-dilutive funding from the FSHD Canada Foundation will support clinical development without equity dilution..
Neil Camarta, co-founder of the FSHD Canada Foundation and a person living with FSHD, underscored the desire for treatments that could potentially restore lost muscle.
Analyst coverage remains constructive with recent "Buy" ratings and targets from LifeSci Capital (US$22) and H.C. Wainwright (US$18).
Preliminary DMD data provide clinical findings that the company believes may be consistent with muscle regeneration; the FSHD trial is expected to evaluate two doses beginning in Q4 2026.
Platform potential extends beyond FSHD and DMD to other degenerative muscle conditions.

Latest News: FDA Clearance and FSHD Canada Partnership

The company announced FDA clearance of its Investigational New Drug application for forazapadin in FSHD, with a randomized, double-blind, placebo-controlled Phase 2 study slated to begin in Q4 2026 evaluating 60 mg and 120 mg doses in adults.

The FSHD Canada Foundation committed up to US$5 million in non-dilutive milestone funding over five quarters in exchange for capped revenue-sharing interest.

Forazapadin Could Fill the FSHD Market Gap

FSHD affects an estimated 800,000 individuals worldwide and is caused by abnormal DUX4 gene activation, leading to progressive muscle weakness, with symptoms often starting in the face, shoulders, and upper arms. There are currently no approved disease-modifying therapies. Forazapadin targets AAK1 and is being investigated for its potential to restore natural muscle repair and regeneration processes disrupted by the disease.

Neil Camarta, co-founder of the FSHD Canada Foundation, provided a human-interest perspective: "People living with FSHD, like me, are eager to find treatments that can stop our muscles from getting weaker. But we would also like to get some of those muscles back. That is what makes this announcement so meaningful. Seeing forazapadin advance into clinical trials to evaluate the potential for muscle regeneration in FSHD is an important step for our community. While we know there is still a long road ahead, it is encouraging to see innovative approaches like this moving into the clinic. FSHD Canada appreciates the support we received from our friends at Solve FSHD, the FSHD Society, and FSHD Global in helping make this possible. Time is muscle!"

Satellos CEO Frank Gleeson noted the broader approach: "We believe the biology targeted by forazapadin has the potential to address significant unmet needs in degenerative muscle diseases, and our expansion into FSHD reflects the broad potential of our muscle regeneration approach."

Chief Medical Officer Wildon Farwell, M.D., added: "We are excited to receive FDA clearance of our IND application for forazapadin in a second disease indication, one for which there are currently no approved therapies. FSHD is a genetic disease in which muscle regeneration appears to be compromised."

Around 30 Million Americans Live with a Rare Disease

The agency reported that exactly half of its 46 novel drug approvals in 2025 were for rare diseases, while 123 orphan new molecular entities were approved over the five years through 2025. The FDA also noted that small patient populations, heterogeneous disease characteristics, and limited understanding of natural disease progression can complicate rare-disease clinical trials.

H.C. Wainwright maintained a "Buy" rating and US$18.00 target in September.

Regulatory approaches are also evolving to address the challenges of rare-disease development.

In 2025, the FDA introduced its Rare Disease Evidence Principles, outlining a framework for therapies targeting rare diseases with very small patient populations and significant unmet medical need driven by known genetic defects. The framework allows FDA and developers to consider evidence such as biomarkers, mechanistic data, pharmacodynamic measurements, natural-history studies, and nonclinical models alongside clinical trial results. For rare inherited diseases such as FSHD, these approaches can be relevant because the number of eligible patients may limit the feasibility of large, conventional randomized trials.

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

What Analysts and Newsletter Writers Are Saying

Recent constructive coverage highlights the expansion potential.

LifeSci Capital reiterated a "Buy" rating with a US$22.00 target on September 25, 2026.

H.C. Wainwright also maintained a "Buy" rating and US$18.00 target in September.

Oppenheimer reiterated a "Buy" rating with a US$40.00 target on September 24, 2026, while Guggenheim reiterated a "Buy" rating with a US$23.00 target in August 2026.

On September 28, 2026, Chen Lin of What is Chen Buying? What is Chen Selling? weighed in on Satellos' latest news, writing that the company "announced the new IND of FSHD was quickly approved by the FDA. FSHD currently has no proven therapy, and the market size is about 3x DMD, according to management. They also got a non-dilutive grant of US$5 million from the FSHD foundation, highlighting the urgent need for a cure. According to the management, MSLE has other "low-hanging fruits" of DM1, BMD, etc., at least 10x the market size of DMD. Given my experience of DMD, Sarepta Therapeutics Inc. (SRPT:NASDAQ) used to be worth US$20 billion not long ago, regarded as the only hope of treating DMD. I can see MSLE could be worth north of US$100 billion if everything is successful, maybe US$50 billion on the conservative side. Today, MSLE has a market cap around only US$200 million. Even though they would likely do a money raiser after the positive results, 100x is possible. Of course, MSLE needs to hit the end points of the current trial, which should be fully enrolled this week."

Broader Potential Uses in the Pipeline

Satellos is currently advancing SAT-3247 through its ongoing Phase 2 BASECAMP and TRAILHEAD studies in children and adults living with Duchenne Muscular Dystrophy, according to its investor presentation.

Satellos plans to initiate the FSHD Phase 2 in Q4 2026 while advancing its DMD studies, with the non-dilutive funding and regulatory clearance providing near-term catalysts for the muscle regeneration approach. [OWNERSHIP_CHART-11545]

Ownership & Share Information¹

Satellos Bioscience Inc. has a market cap of approximately CA$258.63 million, with 21.22 million shares outstanding. The company's 52-week range is CA$7.56-CA$18.98.

Institutions own 49.70% of shares, while Management & Insiders own 6.45%. The remaining 43.85% of shares are Retail.

Frequently Asked Questions

Q: What gap does forazapadin target in FSHD?

A: FSHD has no approved disease-modifying treatments; forazapadin aims to restore compromised muscle regeneration via AAK1 inhibition, as highlighted in the September 24 announcement and patient quotes.

Q: How does the FSHD Canada partnership work?

A: The foundation provides up to US$5 million in milestone payments over five quarters for a capped future FSHD revenue share, supplying non-dilutive capital.

Q: Are there analyst notes on the FSHD expansion?

A: Recent analyst notes support the overall platform; LifeSci Capital reiterated a Buy rating with a US$22 target on September 25, 2026.

Q: What other uses are possible?

A: The company plans to pursue additional muscle diseases and injury conditions where muscle repair restoration may help, building on DMD and now FSHD programs.

Q: What is facioscapulohumeral muscular dystrophy (FSHD)?
A: Facioscapulohumeral muscular dystrophy (FSHD) is a genetic muscle disease characterized by progressive weakness and loss of skeletal muscle. Symptoms commonly affect muscles of the face, shoulder blades, and upper arms before potentially spreading to other parts of the body.

Q: What is muscle regeneration?
A: Muscle regeneration is the biological process through which damaged or injured skeletal muscle repairs itself by replacing or rebuilding muscle tissue. Treatments designed to enhance muscle regeneration aim to restore or increase the body's ability to repair muscle that has been damaged by disease.

Q: What is an AAK1 inhibitor?
A: An AAK1 inhibitor is a drug designed to block the activity of AP2-associated kinase 1 (AAK1), an enzyme involved in cellular signaling and other biological processes. Researchers are investigating whether modulating AAK1 can influence pathways involved in muscle repair and regeneration.

Q: What is an Investigational New Drug (IND) application?
A: An Investigational New Drug (IND) application is a submission to the U.S. Food and Drug Administration that allows a company to seek authorization to administer an investigational drug to people in clinical trials. FDA clearance of an IND permits the proposed clinical investigation to proceed subject to applicable regulatory requirements.

Q: What is a Phase 2 clinical trial?
A: A Phase 2 clinical trial evaluates an investigational treatment in people with the target disease or condition to gather additional information about its safety, dosing, and potential effectiveness. Phase 2 studies generally involve more participants than Phase 1 trials and can help determine the dose or treatment regimen to evaluate in later-stage studies.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: MSCL:TSX;MSLE:NASDAQ, )

Rocket Pharmaceuticals Advances Danon Disease Gene Therapy Trial With FDA Alignment

Thu, 24 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/24/2026

Rocket Pharmaceuticals Inc. (RCKT:NASDAQ) receives FDA alignment to continue its Phase 2 RP-A501 trial for Danon disease, with nine additional patients expected to be treated by mid-2027.

Key Takeaways

Rocket Pharmaceuticals received FDA alignment to continue dosing in its Phase 2 trial of RP-A501 for Danon disease.
The pivotal efficacy population will include 12 male patients treated at the recalibrated dose.
Three patients have already been treated under the modified protocol, leaving nine additional patients to be enrolled and treated.
No evidence of thrombotic microangiopathy or capillary leak syndrome was observed in the first three patients after at least four weeks of follow-up.
Rocket expects to complete dosing of the remaining nine patients by mid-2027.

FDA Review Finds No Reported Signs of Key Safety Events

On September 15, 2026, Rocket Pharmaceuticals Inc. (RCKT:NASDAQ) announced alignment with the U.S. Food and Drug Administration (FDA) on continued enrollment and dosing in its global pivotal Phase 2 trial of RP-A501 for Danon disease. The FDA confirmed the pivotal efficacy population will comprise 12 male patients treated with the recalibrated dose of 3.8 × 10¹³ genome copies per kilogram (GC/kg) using a commercial-grade product. The first three patients treated under the modified protocol will count toward the pivotal population, leaving nine additional patients to be enrolled and treated.

According to the release, the FDA's review included initial safety data from the first three patients treated at the recalibrated dose. All three patients had completed at least four weeks of follow-up care and had been discharged following observation. No clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome was observed. Following its review, the FDA confirmed that enrollment and dosing can continue under the modified protocol.

The study will use the previously established 12-month co-primary endpoints, with the primary assessment based on myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index. These endpoints are intended to support a potential accelerated approval pathway for RP-A501. The modified protocol includes a recalibrated dose, an immunomodulatory regimen comprising rituximab, sirolimus, and corticosteroids, enhanced eligibility criteria, additional safety monitoring, and risk-mitigation measures. Rocket expects to complete dosing of the remaining nine patients by mid-2027.

Nonclinical bridging data supporting the recalibrated dose showed that, in a Danon disease mouse model, administration of Phase 2 material at 3.8 × 10¹³ GC/kg resulted in cardiac LAMP2B protein expression comparable to that observed at a higher dose, along with comparable vector biodistribution.

"FDA's confirmation of the pivotal efficacy framework marks an important milestone for RP-A501 and the Danon disease community," said Gaurav Shah, MD and CEO of Rocket Pharmaceuticals. "With the first three patients counting toward the 12-patient pivotal population and the established co-primary endpoints preserved, we now have a clear and actionable path to complete the pivotal study. The initial clinical experience at the recalibrated dose and supportive product-bridging data further reinforce the path forward."

Rocket Pharmaceuticals is a U.S.-based commercial-stage biotech company focused on developing treatments for cardiovascular disorders, hematological diseases, and immune diseases.

Gene Therapy Programs Target Underlying Causes of Rare Diseases

Danon disease is a rare, inherited disorder that can cause severe cardiac and skeletal muscle disease, with limited treatment options and no established disease-modifying therapy. The condition is caused by pathogenic variants in the LAMP2 gene and is typically more severe in males, with cardiac involvement often including hypertrophic or dilated cardiomyopathy. According to GeneReviews, the prevalence of Danon disease in the general population is not known, although studies have identified pathogenic LAMP2 variants in approximately 1% to 4% of people with hypertrophic cardiomyopathy. The rarity of the disease can make diagnosis, clinical-trial recruitment, and the development of conventional efficacy datasets challenging.

The broader rare-disease market has become an increasingly active area of drug development. The U.S. Food and Drug Administration (FDA) estimates that approximately 25 million to 30 million Americans live with a rare disease, encompassing roughly 10,000 rare diseases and conditions. The agency reported that exactly half of its 46 novel drug approvals in 2025 were for rare diseases, while 123 orphan new molecular entities were approved over the five years through 2025. The FDA also noted that small patient populations, heterogeneous disease characteristics, and limited understanding of natural disease progression can complicate rare-disease clinical trials.

On September 16, 2026, Needham & Company analyst Gil Blum upgraded the company from a Hold to a Buy, giving it a price target of US$9.

Regulatory incentives are intended to encourage development in these smaller patient populations. Under the FDA's orphan-drug program, drugs and biologics targeting diseases affecting fewer than 200,000 people in the U.S. can qualify for orphan designation and associated incentives, including tax credits for qualified clinical trials, potential exemption from certain user fees, and seven years of market exclusivity following approval. The FDA reported that its Office of Orphan Products Development received 657 original orphan-drug designation requests in fiscal 2025 and granted 450 designations.

Gene therapy is an important area of development for inherited rare diseases because it can potentially address the underlying genetic cause rather than only managing symptoms. The FDA's Center for Biologics Evaluation and Research oversees cellular and gene therapy products, including products designed to modify or replace genetic material. Recent approvals have expanded the number of gene therapies available for rare inherited conditions, including pediatric diseases. At the same time, the FDA has acknowledged that the small patient populations typical of rare genetic diseases can make traditional clinical development difficult.

Analysts Anticipate Company Movement

Two analysts commented on Rocket Pharmaceuticals after the company's September 15, 2026, announcement.

Yun Zhong, Ph.D., of Wedbush expressed a positive impression of the release, writing, "We remain optimistic in an ultimate FDA approval, potentially in 1H29, following completion of all patient dosing in the pivotal Ph2 study by mid-2027." Zhong reiterated a "Buy" rating and price target of US$15.

On the same day, Patrick Dolezal of LifeSci Capital also maintained its price target of US$12, giving the company an "Outperform" rating and citing the announcement as "a meaningful clearing for the company."

On September 16, 2026, Needham & Company analyst Gil Blum upgraded the company from a Hold to a Buy, giving it a price target of US$9, according to MarketBeat.

Rocket Advances Toward 2027 RP-A501 Dosing Completion

Dolezal's research report collated upcoming potential catalysts for Rocket Pharmaceuticals, including:

H2 2026: First patient dosing in the Phase 1 study of RP-A701 in BAG3-DCM
H2 2026: RP-A601 PKP2-ACM program update following FDA alignment
Q4 2026: KRESLADI expected commercial supply and patient onboarding
Mid-2027: Completion of pivotal Phase 2 trial dosing for RP-A501 in Danon

Ownership & Share Information¹

Rocket Pharmaceuticals Inc. has a market cap of US$367.74, with 109.77 million shares outstanding. The company's 52-week range is US$2.53-US$5.45. [OWNERSHIP_CHART-11716]

Institutions own 91.46% of shares, while Management & Insiders own 3.16%. The remaining 5.38% of shares are Retail.

Frequently Asked Questions

Q: What is RP-A501?
A: RP-A501 is Rocket Pharmaceuticals' investigational gene therapy being evaluated as a potential treatment for Danon disease.

Q: What is Danon disease?
A: Danon disease is a rare inherited disorder caused by pathogenic variants in the LAMP2 gene. It can affect the heart and skeletal muscles and is generally more severe in males.

Q: How does Danon disease affect the heart?
A: Cardiac manifestations can include hypertrophic cardiomyopathy, in which the heart muscle becomes abnormally thick, and dilated cardiomyopathy, in which the heart becomes enlarged and weakened.

Q: How common is Danon disease?
A: The prevalence of Danon disease in the general population is not known. GeneReviews notes that pathogenic LAMP2 variants have been identified in approximately 1% to 4% of people with hypertrophic cardiomyopathy in certain studies.

Q: What did the FDA agree to regarding RP-A501?
A: The FDA confirmed that Rocket can continue enrollment and dosing under the modified Phase 2 protocol. The pivotal efficacy population will consist of 12 male patients treated with the recalibrated dose using a commercial-grade product.

Q: What is the RP-A501 dose being studied?
A: The recalibrated dose is 3.8 × 10¹³ genome copies per kilogram, or GC/kg.

Q: What are the primary endpoints of the Phase 2 trial?
A: The trial uses 12-month co-primary endpoints based on myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index.

Q: What is LAMP2 protein?
A: LAMP2 is a protein involved in cellular processes, including lysosomal function. Danon disease results from pathogenic variants in the LAMP2 gene, which can lead to abnormal cellular function and tissue damage.

Q: What is left ventricular mass index?
A: Left ventricular mass index is a measurement of the mass of the heart's left ventricle adjusted for body size. It can be used to assess changes in heart muscle thickness and cardiac structure.

Q: What is an accelerated approval pathway?
A: Accelerated approval is an FDA pathway that can allow approval of certain drugs for serious conditions based on a surrogate endpoint that is reasonably likely to predict clinical benefit, subject to requirements for confirmatory evidence where applicable.

Q: What is the modified RP-A501 protocol?
A: The modified protocol includes the recalibrated dose, an immunomodulatory regimen using rituximab, sirolimus, and corticosteroids, enhanced eligibility criteria, additional safety monitoring, and risk-mitigation measures.

Q: Why was the RP-A501 dose recalibrated?
A: Rocket conducted nonclinical bridging studies to evaluate the recalibrated dose. In a Danon disease mouse model, the 3.8 × 10¹³ GC/kg dose produced cardiac LAMP2B protein expression comparable to that observed at a higher dose, along with comparable vector biodistribution.

Q: When does Rocket expect to complete RP-A501 dosing?
A: Rocket expects to complete dosing of the remaining nine patients by mid-2027.

Q: What other programs are part of Rocket's pipeline?
A: Rocket is developing programs for cardiovascular and other genetic diseases, including RP-A701 for BAG3 dilated cardiomyopathy and RP-A601 for PKP2 arrhythmogenic cardiomyopathy.

Q: What is a rare disease?
A: In the U.S., the FDA generally defines a rare disease or condition as one affecting fewer than 200,000 people. Rare diseases often have small patient populations, which can make clinical-trial recruitment and conventional efficacy studies more difficult.

A: Why is gene therapy being studied for Danon disease?
A: Because Danon disease is caused by mutations in the LAMP2 gene, gene therapy is being investigated as a potential way to address the underlying genetic cause rather than treating only the symptoms or consequences of the disease.

Q: What is the FDA's Rare Disease Evidence Principles framework?
A: The FDA's Rare Disease Evidence Principles provide a framework for evaluating therapies for rare diseases with very small patient populations. The framework allows consideration of evidence such as biomarkers, pharmacodynamic measurements, natural-history data, mechanistic evidence, and nonclinical models alongside clinical trial results.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: RCKT:NASDAQ, )

Fennec Pharmaceuticals Reports PEDMARK Data Showing Reduced Hearing Loss in Japanese Study

Wed, 23 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/23/2026

Fennec Pharmaceuticals Inc. (FENC:NASDAQ;FRX:TSE) reports Phase 2 STS-J01 results for PEDMARK in Japan, with ASHA-defined hearing loss in 24% of patients versus a 56.4% benchmark.

Key Takeaways

Fennec Pharmaceuticals reported positive hearing-loss results from the Phase 2 STS-J01 study of PEDMARK in Japan.
ASHA-defined hearing loss occurred in 24% of patients, compared with a 56.4% historical benchmark.
76% of patients remained free of ASHA-defined hearing loss, and no Grade 3 or Grade 4 hearing loss was reported.
Objective tumor responses were observed in 23 of 24 evaluable patients.
Fennec is pursuing Japanese registration for PEDMARK and evaluating potential partnering or licensing opportunities.

Fennec Develops Treatments for Cancer-Related Hearing Loss

On September 17, 2026, Fennec Pharmaceuticals Inc. (FENC:NASDAQ; FRX:TSX) announced detailed results from the investigator-initiated Phase 2 STS-J01 clinical study of its PEDMARK (sodium thiosulfate injection) in Japan. The results, presented at the 58th Annual International Society of Pediatric Oncology (SIOP) Annual Meeting, evaluated PEDMARK for reducing cisplatin-induced hearing loss in pediatric and adolescent and young adult (AYA) patients with localized, non-metastatic solid tumors.

The study enrolled 33 patients across 11 institutions in Japan, including 27 patients in the primary cohort and six in exploratory cohorts. Among the 25 patients in the primary efficacy population, ASHA-defined hearing loss occurred in 24% of patients, compared with a prespecified historical benchmark of 56.4%. Additional hearing-related results included:

19 of 25 patients, or 76%, remained free of ASHA-defined hearing loss
84% of patients had Grade 0 hearing loss under Brock criteria
No Grade 3 or Grade 4 hearing loss was observed
Objective tumor responses were observed in 23 of 24, or 95.8%, of evaluable patients

Prospective pharmacokinetic analyses also examined the interaction between PEDMARK and cisplatin-derived platinum, providing additional data supporting the administration of PEDMARK six hours after cisplatin. According to the press release, Fennec believes that the findings add to evidence from the Phase 3 Children's Oncology Group ACCL0431 and SIOPEL 6 studies, with STS-J01 representing the third study to report that PEDMARK did not interfere with cisplatin's antitumor activity. The study's safety findings were consistent with the known tolerability profile of PEDMARK and the expected toxicities associated with cisplatin-containing chemotherapy, with no serious adverse event attributed to PEDMARK and no Grade 4 PEDMARK-related toxicity reported.

Fennec is pursuing registration of PEDMARK in Japan and is exploring partnering or licensing opportunities for the drug. PEDMARK has been approved by the U.S. Food and Drug Administration to reduce the risk of cisplatin-associated ototoxicity in pediatric patients one month of age and older with localized, non-metastatic solid tumors. The press release stated that the National Comprehensive Cancer Network also recommends PEDMARK for the adolescent and young adult population with a Category 2A endorsement.

Fennec is a specialty pharmaceutical development company that is specifically focused on treating ototoxicity in cancer patients who receive cisplatin-based chemotherapy. The company is based in North Carolina.

Pediatric Oncology Remains an Active Area of Drug Development

Pediatric oncology represents a relatively small portion of the broader cancer market, but it remains an active area of drug development. In the U.S., an estimated 9,550 children from birth through age 14 were diagnosed with cancer in 2025, with about 1,050 expected to die from the disease, according to the National Cancer Institute.

Childhood cancers include leukemia, brain and spinal cord tumors, neuroblastoma, kidney and liver cancers, bone cancers, and other solid tumors. Because many pediatric cancers are relatively rare, clinical development can involve small patient populations and specialized trial designs.

H.C. Wainwright's Raghuram Selvaraju, Ph.D., reiterated a "Buy" rating and 12-month price target of US$16 for Fennec on September 9, 2026.

The broader oncology market provides a significantly larger commercial backdrop. According to IQVIA's Global Oncology Trends 2025 report, global spending on cancer drugs reached US$252 billion in 2024 and is projected to reach US$441 billion by 2029.

Oncology also accounted for 41% of clinical trials started in 2024, with 2,162 oncology trials initiated during the year. IQVIA reported that 74% of oncology trial starts focused on rare cancers, reflecting continued development activity in patient populations with relatively limited treatment options.

Pediatric oncology is also seeing continued expansion in the number and types of available therapies. The U.S. Food and Drug Administration's pediatric oncology data show more than 60 drugs with more than 85 associated indications have been approved for pediatric cancers since the early 1950s. The agency's 2025 Oncology Center of Excellence annual report said 11 approvals covering 12 drugs and biologics resulted in 21 new indications for pediatric patients with cancer during the year. More than half of the novel oncology products approved by the FDA in 2025 were for orphan-designated indications, underscoring the role of rare cancers within oncology drug development.

Experts Eye Fennec's Growth and Corporate Development Plans

H.C. Wainwright's Raghuram Selvaraju, Ph.D., reiterated a "Buy" rating and 12-month price target of US$16 for Fennec on September 9, 2026. " We draw investors' attention to the fact that adoption continues to build across both new and existing accounts, with established prescribers demonstrating growing confidence in PEDMARK (sodium thiosulfate), contributing to deeper utilization and higher vials per account," he wrote.

On September 18, 2026, Chen Lin of What is Chen Buying? What is Chen Selling? weighed in on the company, saying, "I had a good meeting with FENC management. They are almost apologetic about selling some of the stocks they own. They explained to me that they have been with the company for over 10 years and need to pay taxes on the expiring warrants. So, they have to sell some."

Chen continued, "Other than that, the company is doing extremely well. They are hoping for 'triple digits' growth heading into next year. They are hoping for adult indication results by ASCO next year. They were cash flow positive for the first time last quarter and have US$40+ million cash on the balance sheet. Share buyback is one of the options they are considering. They are also at the stage of being acquired or acquiring some new products. I see news about corporate development coming in the next year."

Fennec Advances PEDMARK Registration and International Commercialization

According to Fennec's August 2026 investor presentation, the company is pursuing regulatory registration for PEDMARK in Japan following the STS-J01 study, while also evaluating potential partnering or licensing opportunities in the market.

In Europe, the product is being commercialized as PEDMARQSI through Norgine, which launched the product in Germany and the U.K. in 2025, and has planned additional European launches.

The company has also pointed out continued international commercialization, regulatory activity, and potential milestone payments under its European licensing agreement as areas to watch. [OWNERSHIP_CHART-10683]

Ownership & Share Information¹

Fennec Pharmaceuticals Inc. has a market cap of US$382.49 million, with 35.06 million shares outstanding. The company's 52-week range is US$5.65-US$13.25.

Institutions own 54.34% of shares, while Strategic Investors own 11.39%. Management & Insiders own 2.78% of shares, and the remaining 31.49% of shares are held by Retail.

Frequently Asked Questions

Q: What is PEDMARK?
A: PEDMARK is the brand name for sodium thiosulfate injection, a drug designed to reduce the risk of cisplatin-associated hearing loss in pediatric patients receiving treatment for localized, non-metastatic solid tumors.

Q: What is cisplatin?
A: Cisplatin is a chemotherapy drug used to treat a range of cancers. One of its known side effects is ototoxicity, which can damage the inner ear and cause hearing loss.

Q: What is ototoxicity?
A: Ototoxicity refers to damage to the structures of the inner ear caused by certain medications or other substances. In patients receiving cisplatin, it can result in permanent hearing loss.

Q: What was the STS-J01 study?
A: STS-J01 was an investigator-initiated Phase 2 study in Japan evaluating PEDMARK for reducing cisplatin-induced hearing loss in pediatric, adolescent, and young adult patients with localized, non-metastatic solid tumors.

Q: How many patients participated in STS-J01?
A: The study enrolled 33 patients across 11 institutions in Japan. The primary cohort included 27 patients, while six additional patients were enrolled in exploratory cohorts.

Q: What were the main hearing-loss results?
A: Among the 25 patients in the primary efficacy population, 24% experienced ASHA-defined hearing loss, compared with a prespecified historical benchmark of 56.4%. Nineteen of the 25 patients, or 76%, remained free of ASHA-defined hearing loss.

Q: What is ASHA-defined hearing loss?
A: ASHA refers to the American Speech-Language-Hearing Association. In the STS-J01 study, ASHA criteria were used to evaluate hearing loss and determine the study's primary efficacy outcome.

Q: What were the Brock hearing-loss results?
A: Under the Brock criteria, 84% of patients had Grade 0 hearing loss. No Grade 3 or Grade 4 hearing loss was observed.

Q: Did PEDMARK appear to interfere with cisplatin's cancer-fighting activity?
A: The study's pharmacokinetic analyses provided additional data supporting the administration of PEDMARK six hours after cisplatin. According to Fennec, the STS-J01 findings add to evidence from the Phase 3 ACCL0431 and SIOPEL 6 studies indicating that PEDMARK did not interfere with cisplatin's antitumor activity.

Q: What tumor responses were observed in STS-J01?
A: Objective tumor responses were observed in 23 of 24 evaluable patients, or 95.8%. These results were reported alongside the study's hearing-related findings.

Q: Was PEDMARK well-tolerated in the study?
A: Fennec reported that safety findings were consistent with the known tolerability profile of PEDMARK and the expected toxicities associated with cisplatin-containing chemotherapy. No serious adverse event was attributed to PEDMARK, and no Grade 4 PEDMARK-related toxicity was reported.

Q: Is PEDMARK approved in the U.S.?
A: Yes. The U.S. Food and Drug Administration has approved PEDMARK to reduce the risk of cisplatin-associated ototoxicity in pediatric patients one month of age and older with localized, non-metastatic solid tumors.

Q: What is Fennec pursuing in Japan?
A: Fennec is pursuing regulatory registration of PEDMARK in Japan following the STS-J01 study results. The company is also exploring potential partnering or licensing opportunities for the product in the Japanese market.

Q: What is PEDMARQSI?
A: PEDMARQSI is the European brand name for the product. It is being commercialized in Europe through Fennec's partnership with Norgine, which launched the product in Germany and the U.K. in 2025 and has planned additional European launches.

Q: How large is the broader oncology market?
A: According to IQVIA's Global Oncology Trends 2025 report, global spending on cancer medicines reached US$252 billion in 2024 and was projected to reach US$441 billion by 2029. Oncology accounted for 41% of clinical trials initiated in 2024.

Q: Why is hearing preservation important during pediatric cancer treatment?
A: Hearing loss can be a lasting consequence of cisplatin treatment, and preserving hearing can be particularly important for children and young people because hearing affects communication, education, and development. PEDMARK is intended to reduce this treatment-related risk while allowing patients to receive cisplatin-based chemotherapy.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: FENC:NASDAQ;FRX:TSX, )

Coya Enrolls 100 Patients in Phase 2/3 ALS Trial of COYA 302

Tue, 22 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/22/2026

Coya Therapeutics reaches 100-patient enrollment in its Phase 2/3 ALSTARS trial for COYA 302 in ALS, with full enrollment and topline data expected soon. Learn key catalysts for investors.

Coya Therapeutics Inc. (COYA:NASDAQ) has now reached the 100th participant enrolled in its Phase 2/3 ALSTARS trial of COYA 302 for amyotrophic lateral sclerosis (ALS). The 100th participant was enrolled. This milestone moves the company closer to completing the planned 120-participant target.

Full enrollment is projected within weeks, positioning the firm for topline data readout in early Q2 2027. The randomized, multicenter, double-blind, placebo-controlled study tests two dosing regimens of COYA 302 against placebo.

Why the Enrollment Progress Matters for Investors Now

Reaching 100 participants signals steady recruitment momentum in a disease area with high unmet need. ALS is a progressive neurodegenerative condition that affects motor neurons controlling voluntary muscles used for speaking, swallowing, and breathing. Positive results could support further development steps and strengthen the company's position.

The trial includes a 24-week double-blind treatment phase followed by a 24-week blinded active-treatment extension, allowing up to 48 weeks of data collection. The primary endpoint tracks the change in disease severity from baseline to Week 24 using the ALSFRS-R score versus placebo. Secondary measures cover safety, tolerability, biological activity, and biomarker levels.

Key Investor Takeaways

Coya has enrolled 100 of 120 planned participants in the Phase 2/3 ALSTARS trial, with completion expected shortly and topline data targeted for early Q2 2027.
COYA 302 combines low-dose interleukin-2 and CTLA-4 immunoglobulin and holds an FDA Fast Track designation in ALS.
Additional data from ALS and Alzheimer's programs are anticipated in the second half of 2026.
Analysts from H.C. Wainwright, Roth, and Lake Street maintain Buy ratings with price targets of US$18, US$12, and US$17, respectively.
The company is Houston-based and focuses on regulatory T cell therapies to address inflammation.
Market cap stands at approximately US$111.66 million with 23.46 million shares outstanding.

Company Position and Pipeline Assets

Coya Therapeutics develops treatments that modulate regulatory T cells to reduce systemic and neuroinflammation. COYA 302 represents the lead candidate currently in the ALSTARS trial. The company also plans to release single-cell proteomics data from earlier ALS and Alzheimer's studies in the second half of 2026, along with the potential publication of COYA 303 in vivo data.

A successful ALSTARS outcome could support a potential Biologics License Application filing pathway and possible commercialization steps in 2028.

Broader Sector Timing and Funding Environment

The U.S. government provided US$90 million in federal funding for ALS research. Global medicine use trends point to growth in innovative therapeutics through 2030, particularly in areas such as oncology and immunology. IQVIA discussed the global pharma market projection for 2026.

Pharma funding patterns showed mixed results between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. Global biotech deals reached US$228.4 billion in 2025. J. Edward Moreno of Sherwood News reported R&D spending among top pharmaceutical companies declined 3.6 percent in 2025. BCG talked about trends biopharma companies need to be aware of in 2026 at the start of the year.

Views and Valuation Context

Analysts continue to highlight the upcoming data readouts. Raghuram Selvaraju of H.C. Wainwright reiterated a Buy rating and US$18 price target, noting that positive ALSTARS data could support pivotal development in ALS late in 2027.

Roth analyst Boobalan Pachaiyappan maintained a Buy rating and US$12 target, citing the potential for a 2.5-point ALSFRS-R improvement to support a BLA filing.

Lake Street's Chad Messer reiterated a Buy rating and US$17 target, emphasizing that full enrollment, Phase 2/3 status, and Fast Track designation strengthen the investment case.

Newsletter writer Chen Lin observed steady enrollment of four to five patients per week and noted the competitive landscape after a competitor halted an ALS program. [OWNERSHIP_CHART-11262]

Share Structure and Near-Term Events¹

Coya Therapeutics Inc. has a market cap of US$111.66 million and 23.46 million shares outstanding. The 52-week range is US$3.71 to US$7.75.

Institutions hold 33.23 percent, strategic investors hold 13.69 percent, management and insiders hold 1 percent, and retail investors hold the remaining 52.08 percent.

Common Questions from Investors

Q: What is the primary endpoint in the ALSTARS trial?
A: The primary endpoint measures change in ALS disease severity from baseline through Week 24 using the ALSFRS-R total score compared with placebo.

Q: What does the Fast Track designation provide?
A: FDA Fast Track designation for COYA 302 in ALS is intended to facilitate development and expedite review of drugs addressing serious conditions with unmet medical needs.

Q: When is topline data expected?
A: Topline data from the ALSTARS trial is targeted for early Q2 2027 following completion of the 120-participant enrollment.

Q: What are the next data catalysts after enrollment?
A: Additional single-cell proteomics data from ALS and Alzheimer's studies, plus a potential COYA 303 publication, are planned for the second half of 2026.

Investors should weigh clinical, regulatory, and financing risks typical of development-stage biotechnology companies when evaluating the stock.

Important Disclosures:

Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: COYA:NASDAQ, )

The Life Sciences Report

Diabetes Cell Therapy Merger Nears Close Ahead of Q1 2027 First Patient Dosing

Key Investor Takeaways

Sernova and Seraxis Near BetaNova Merger

From Merger to First Patient

Raise Tops Its Target

Two Analysts Like the Match

9.5 Million and Counting

Ownership and Share Structure1

Common Questions from Investors

Virtual Care Platform Grows US Visits 56%, Eyes Record Quarter

Key Investor Takeaways

53,348 Visits and a Record Quarter in Sight

US Growth Outruns the Cash Register

Built by Doctors, Open to 24 Million Insured Americans

Buy Rating Holds as US Traction Builds

A US$5.3 Trillion Problem Meets a Virtual Fix

Ownership and Share Information1

Common Questions from Investors

NervGen Kicks Off Pivotal Phase 3 Test of NVG-291 in Chronic Spinal Cord Injury

Key Investor Takeaways

NervGen Launches Pivotal Test of Its Spinal Cord Repair Drug

Inside the RESTORE Study

The Data and the Dollars Behind Phase 3

Wall Street Says Buy, One Investor Says Wait

The Unmet Need Behind NVG-291

Ownership and Share Information1

Common Questions from Investors

MindBio Therapeutics Advances Voice AI Kiosk for Intoxication Detection Toward Commercial Pilot

Key Investor Takeaways

Latest News: Kiosk Manufacturing Milestone

Addiction in Mining: A Serious Danger

MindBio's Tech Could Prevent Injury

A Multi-Sector Future

Ownership & Share Information1

Frequently Asked Questions

The FDA Clarified Its Rules for Medical AI. This Stock Could Be on the Right Side of Them

Key Investor Takeaways

As AI Healthcare Laws Tighten, Physician-Led Technology Could Gain an Edge

FDA Revises Clinical Decision-Support Rules

States Move to Restrict Autonomous Medical AI

Rocket Doctor's Global Library of Medicine Keeps Physicians Involved

Alea Health Acquisition Expands Mental Healthcare Strategy

NIH Funding Supports AI Medical History Development

US Patient Visits Nearly Triple as Revenue Grows

Insurance Infrastructure and AI Investment Could Strengthen Competitive Position

Ownership & Share Information2

Frequently Asked Questions About Rocket Doctor AI Stock and Healthcare AI Regulations

Nvidia Commits US$1B to American Science Push in Tech, Energy, and Healthcare

Key Investor Takeaways

US$1 Billion Commitment to US Scientific Leadership

The AI Sector's Rapid Growth

Recent Analyst Coverage is a 'Buy'

Catalysts for the Tech Giant

Ownership & Share Information1

Frequently Asked Questions

Solving a 10,000-Pound Problem: This Company Aims to Reinvent the Brain Scan

Why Alzheimer's Imaging Has Taken on New Importance

A Smaller Scanner Changes the Equation

Florida Becomes the First Test

From One Clinic to a National Network

Ownership and Share Structure2

Key Investor Takeaways

Frequently Asked Questions

Sernova and Seraxis Bet on BetaNova to Take Diabetes Cell Therapy Into the Clinic

Key Investor Takeaways

Merger Moves Ahead With 2027 Trial in Sight

Inside the BetaNova Combination

Management of Both Companies Buys In

Type 1 Diabetes: A Growing Patient Base and Treatment Market

Analysts See a Fit in the BetaNova Combination

Ownership and Share Structure1

Common Questions from Investors

Nektar's Phase 2b Data Shows Durable Eczema, Alopecia Response

Key Investor Takeaways

EADV 2026 Data on Rezpegaldesleukin

How Nektar's Treg Approach Addresses Gaps in the Eczema and Alopecia Markets

What's Going on Now?

Analysts Reporting Varying Valuations

Nektar's Next Steps

Ownership and Share Structure¹

Ownership and Share Information¹

Ownership and Share Information¹

Ownership & Share Information¹

Ownership & Share Information²

Ownership & Share Information¹

Ownership and Share Structure²

Ownership and Share Structure¹

Ownership & Share Information¹

Ownership and Share Structure¹

Ownership & Share Information¹

Ownership & Share Information¹

Ownership & Share Information¹

Ownership & Share Information¹

Share Structure and Near-Term Events¹